Financial Reporting Considerations Related to COVID-19 and an Economic Downturn

This document was updated to reflect changes as a result of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and other accounting and financial reporting developments associated with the coronavirus disease 2019 (“COVID-19”) pandemic. Modified text has been marked with a **boldface italic date** in brackets throughout the document, and Appendix D summarizes the changes. Note that additional updates to this publication may be issued in the future, as warranted.

**Executive Summary**

The COVID-19 pandemic is affecting major economic and financial markets, and virtually all industries and governments are facing challenges associated with the economic conditions resulting from efforts to address it. For example, many entities in the travel, hospitality, leisure, and retail industries have seen sharp declines in revenues due to regulatory and organizational mandates (e.g., “shelter in place” mandates, school closures) and voluntary changes in consumer behavior (e.g., “social distancing”). To address these economic challenges, some governments are pursuing laws or other related initiatives. For example, in March 2020, the United States government enacted several new laws, most notably the CARES Act, which provides $2.2 trillion of economy-wide financial stimulus. See Deloitte’s April 9, 2020, *Heads Up* for further information about the CARES Act and related financial reporting considerations. [Paragraph updated April 13, 2020]

---

1 On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic.
As the spread of the pandemic increases, entities are experiencing conditions often associated with a general economic downturn, including, but not limited to, financial market volatility and erosion of market value, deteriorating credit, liquidity concerns, further increases in government intervention, increasing unemployment, broad declines in consumer discretionary spending, increasing inventory levels, reductions in production because of decreased demand and supply constraints, layoffs and furloughs, and other restructuring activities. The continuation of these circumstances could have a prolonged negative impact on an entity's financial condition and results.

This Financial Reporting Alert discusses certain key accounting and financial reporting considerations related to conditions that may result from the COVID-19 pandemic as well as various industry-specific considerations. The significance of the topics discussed will of course vary by industry and entity, but we believe that the following accounting and reporting issues will be the most pervasive and challenging as a result of the pandemic's impact:

- **Preparation of forward-looking cash-flow estimates** — The use of forward-looking information is pervasive in an entity's assessment of, among other things, the impairment of nonfinancial assets (including goodwill), the realizability of deferred tax assets, and the entity's ability to continue as a going concern. Unique complexities associated with preparing forward-looking information as a result of the pandemic and economic downturn include the following:
  
  - There is an extremely wide range of possible outcomes. A recent headline expresses this dilemma well — “Infectious Disease Experts Don't Know How Bad the Coronavirus Is Going to Get, Either.” There is a particularly high degree of uncertainty about the ultimate trajectory of the pandemic and the path and time needed for a return to a “steady state.”
  
  - The associated economic impact of the pandemic is highly dependent on variables that are difficult to predict. Examples include the degree to which governments restrict business and personal activities, the associated level of compliance by citizens, the degree to which “flattening the curve” is successful, and the nature and effectiveness of government assistance.
  
  - Each entity must then translate the effect of those macro conditions into estimates of its own future cash flows.

Nevertheless, entities will need to make good-faith estimates, prepare comprehensive documentation supporting the basis for such estimates, and provide robust disclosure of the key assumptions used and, potentially, their sensitivity to change.

- **Recoverability and impairment of assets** — Perhaps the most acute examples of the increased challenge associated with forward-looking information are the impairment tests for long-lived assets, intangibles, and goodwill. These nonfinancial assets use recoverability and impairment models that rely on the development of cash flow projections that are subject to the significant uncertainties noted above. However, impairments establish a new cost basis for the assets and do not permit the subsequent reversal of the recorded impairment. Good-faith estimates in the current reporting period could result in material recorded impairments; if unforeseen favorable developments occur in subsequent quarters, the recognized impairment would no longer be indicated, but it cannot be reversed.

- **Accounting for financial assets** — Recently, there have been severe declines in the fair value of many financial assets, particularly equity securities. Likewise, the ability of debtors to comply with the terms of loans and similar instruments has been adversely affected. Entities will need to carefully consider and apply the appropriate impairment and loss recognition guidance.

1 https://fivethirtyeight.com/features/infectious-disease-experts-dont-know-how-bad-the-coronavirus-is-going-to-get-either/
• **Contract modifications** — Changes in economic activity caused by the pandemic will cause many entities to renegotiate the terms of existing contracts and arrangements. Examples include contracts with customers, compensation arrangements with employees, leases, and the terms of many financial assets and liabilities. As a result of these changes, entities will need to ensure that the appropriate guidance in U.S. GAAP is considered.

• **Subsequent events** — It may be challenging for an entity to separate recognized and unrecognized subsequent events in a global marketplace that is extremely volatile and in which major developments occur daily (e.g., the stock market’s daily reaction to new information). Although entities may not have all facts “on hand” on the balance sheet date, once such facts are gathered, an assessment must be based on conditions as they existed on the balance sheet date. For entities whose balance sheet date is in February or before, we believe that much of what is known about events related to COVID-19 as of the date of this publication for U.S. operations would be viewed as an unrecognized rather than recognized event (i.e., the information did not reflect conditions as of the balance sheet date). For example, during March 2020, (1) governments enacted “shelter in place” orders, (2) there was a precipitous drop in equity markets, and (3) sweeping restrictions to travel were initiated by corporations and governments. The severe negative impacts on the economy associated with these events were generally not existing conditions as of the end of February. As the global landscape evolves, entities are encouraged to remain vigilant, document the nature and timing of events, and consult with their accounting advisers.

• **Going concern** — As a result of COVID-19 and its associated effects, entities need to consider whether, in their specific circumstances, they have the ability to continue as a going concern within one year after the date on which the interim or annual financial statements are issued (or available to be issued, when applicable). The initial assessment (before consideration of management’s plans) will require an entity to consider, among other things, (1) the extent of operational disruption, (2) potential diminished demand for products or services, (3) contractual obligations due or anticipated within one year, (4) potential liquidity and working capital shortfalls, and (5) access to existing sources of capital (e.g., available line of credit). An entity can only base this initial assessment on information that is available (i.e., known and reasonably knowable) as of the issuance date of the financial statements. An entity may be able to alleviate substantial doubt, if it exists, if it is probable that its plans will be effectively implemented, and, when implemented, will mitigate the conditions that are raising substantial doubt in the first instance and will do so within one year after the issuance date of the financial statements. Further, an entity must provide comprehensive disclosures in its annual and interim financial statements when events and conditions are identified that raise substantial doubt about the entity’s ability to continue as a going concern even when management’s plans alleviate such doubt.

Entities must carefully consider their unique circumstances and risk exposures when analyzing how recent events may affect their financial reporting. Specifically, financial reporting and related financial statement disclosures need to convey all material current or potential effects of the COVID-19 pandemic. It is also critical that management understand the risks entities face and how they are affected by them. Further, SEC registrants must consider whether to disclose information in areas such as MD&A or the risk factors section in addition to their disclosures in the footnotes to the financial statements. The remainder of this Financial Reporting Alert is intended to address these matters and is divided into the following sections:

- Select SEC and PCAOB Announcements Related to COVID-19
- SEC Reporting and Disclosure Considerations
- Broad Financial Reporting and Accounting Considerations
- Requirement to Develop Estimates, and Consistency of Assumptions and Estimates
- Impairment of Nonfinancial Assets (Including Goodwill)
- Financial Instruments and Contract Assets
- Revenue Contracts With Customers
- Exit or Disposal Cost Obligations
- Contingency and Loss Recovery Matters (Loss Contingencies, Recognition of Losses on Firmly Committed Executory Contracts, Future Operating Losses, Contractual Penalties, Insurance Recoveries)
- Lease/Rent Concessions
- Consolidation
- Employee Benefits (Defined Benefit Plans, Stock Compensation Performance Conditions and Service Conditions, Employee Termination Benefits)
- Risks and Uncertainties
- Other Accounting and Reporting Considerations (Long-Term Intra-Entity Foreign Investments, Government Assistance, Income Statement Classification Considerations, Going Concern, Subsequent Events)
- Income Taxes
- Internal Control Considerations
- Financial Reporting Under ASC 852 for Entities in Reorganization Under the Bankruptcy Code
- Appendix A — Industry-Specific Insights
  - Banking and Finance
  - Media and Entertainment
  - Real Estate
  - Oil and Gas
  - Power, Utilities, and Renewables
  - Aerospace and Defense
  - Life Sciences
  - Consumer
    - Transportation (Airlines, Shipping and Logistics, Passenger Ground Transportation)
    - Hospitality and Services (Hotels, Resorts, and Casinos; Restaurants and Food Services; Cruise Lines)
  - Retail
  - Automotive
- Appendix B — Entities Reporting Under IFRS Standards
- Appendix C — Deloitte Contacts and Acknowledgments
- Appendix D — Summary of Updates
Select SEC and PCAOB Announcements Related to COVID-19
[Updated April 13, 2020]

As the COVID-19 pandemic has evolved, the SEC and other regulators have provided guidance and offered companies regulatory relief as well as emphasized the importance of timely, high-quality financial reporting in the current environment. On April 8, 2020, SEC Chairman Jay Clayton and SEC Division of Corporation Finance Director William Hinman released a joint statement highlighting certain perspectives and providing considerations for public companies as they prepare for earnings releases and investor calls. The statement summarizes the guidance and relief the SEC has provided to date, much of which is discussed further below, and stresses the need for timely information regarding a company’s financial and operating status as well as expectations for the future:

Company disclosures should reflect [the] state of affairs and outlook and, in particular, respond to investor interest in: (1) where the company stands today, operationally and financially, (2) how the company’s COVID-19 response, including its efforts to protect the health and well-being of its workforce and its customers, is progressing, and (3) how its operations and financial condition may change as all our efforts to fight COVID-19 progress.

The statement also highlights the importance of public companies’ disclosures of forward-looking information regarding the economic recovery. In addition to providing important information to investors, such information may allow customers, suppliers, and other stakeholders to better plan for the future and help spur economic recovery. Chairman Clayton and Director Hinman also stated that they “would not expect good faith attempts to provide appropriately framed forward-looking information to be second guessed by the SEC” and reminded companies of the safe harbor available under U.S. securities law for such information.

On April 3, 2020, SEC Chief Accountant Sagar Teotia published a statement that also focused on the importance of providing investors with high-quality financial information. The statement emphasizes that the Office of the Chief Accountant (OCA) is “available to help companies, auditors, and others with complex accounting, financial reporting, independence, and auditing issues.” It notes also that the OCA will continue to respect “well-reasoned judgments that entities have made” and recognizes that as a result of COVID-19, entities may need to apply significant judgment in making estimates.

Deadline Relief

While the SEC has continually encouraged public companies to provide timely, high-quality information, it has also acknowledged that there may be instances in which registrants need additional time to gather that information. Consequently, on March 25, 2020, the SEC took several actions (further discussed below), including issuing an order (the “Order”) that extends certain filing deadlines.

The Order gives public entities an additional 45 days from the original due date to file certain reports that would otherwise have been due from March 1 to July 1, 2020, if specified conditions are met. The Order, which supersedes similar relief the SEC had provided on March 4, 2020, grants accommodations in a manner similar to how relief is provided under Exchange Act Rule 12b-25 (Rule 12b-25).3 To use the Order’s relief, a registrant must furnish a current report on Form 8-K (or Form 6-K for foreign private issuers) for each filing that is delayed. The registrant should also ensure that it has disclosed all of the following:

1. That the registrant is relying on the Order.
2. Why the registrant is “unable to meet a filing deadline due to circumstances related to COVID-19.”

---

3. The estimated date by which the related filing will be made.


5. If the reason for a filing delay is related to the inability of a third party to furnish any required opinion, report, or certification, a statement signed by the third party stating the specific reasons that it is unable to furnish the required information.

The SEC's Division of Corporation Finance also issued Compliance & Disclosure Interpretations (C&DI) Exchange Act Rules 135.12 and 135.13 to clarify the interrelationship between relief under the Order and relief under Rule 12b-25. Rule 12b-25 provides registrants with deadline relief of up to 5 days for quarterly reports and 15 days for annual reports. While this relief can be used in combination with the relief provided by the Order, filings must be appropriately sequenced. Because the Order requires a Form 8-K to be filed by the registrant's original due date, a registrant that has filed an extension under Rule 12b-25 would not be able to subsequently take advantage of the relief offered by the Order because the original due date would have passed. However, a registrant that properly files an extension under the Order may then file an extension under Rule 12b-25 at the end of its 45-day extension. This sequencing effectively could lengthen the extension period to 50 days for quarterly reports or 60 days for annual reports.

Registrants that continue to be concerned that COVID-19 could negatively affect their financial reporting quality or ability to meet the modified SEC filing deadlines are encouraged to proactively reach out to their auditors, legal counsel, or the SEC, as appropriate, to consider the availability of additional relief. In addition, registrants may wish to consult with legal counsel regarding how reliance on the Order may affect their access to capital markets.

**Disclosure Guidance**

In addition to the Order, the SEC's Division of Corporation Finance issued CF Disclosure Guidance Topic No. 9, “Coronavirus (COVID-19)” (“DG Topic 9”). That guidance states, in part:

*We understand that reporting companies share the view that timely, robust, and complete information is essential to functioning markets and that they want to file periodic and current reports in a timely manner, notwithstanding the available relief. The Division encourages timely reporting while recognizing that it may be difficult to assess or predict with precision the broad effects of COVID-19 on industries or individual companies.*

DG Topic 9 addresses numerous matters related to the evolving impact of COVID-19, including general disclosure considerations, earnings releases, non-GAAP measures, and material nonpublic information (all of which are discussed further below).

**Other Guidance and Relief**

The SEC has also provided the following COVID-19 related relief and guidance:

- *Material nonpublic information* — Because the potential effects of COVID-19 could constitute material nonpublic information, entities should consider how their codes of ethics and insider trading policies address, prevent, and deter trading that is based on such information. If an entity becomes aware of a material risk related to COVID-19, it should also consider whether and, if so, when to implement trading restrictions until it has appropriately informed investors. Further, on March 23, 2020, Stephanie Avakian and Steven Peikin, co-directors of the SEC's Division of Enforcement, issued a statement emphasizing that it is important for public companies “to be mindful of their established disclosure controls and procedures, insider trading prohibitions, codes of ethics, and Regulation FD and selective disclosure prohibitions to ensure to the greatest extent possible that they protect against the improper dissemination and use of material nonpublic information.”
• **Investment funds and advisers** — The SEC issued two additional orders that give investment funds and advisers (1) relief related to the Investment Company Act of 1940 and (2) relief related to the Investment Advisers Act of 1940. The relief covers in-person board meetings and certain filing and delivery requirements.

• **Proxy rules and annual shareholder meetings** — The SEC published guidance to help public companies, investment companies, shareholders, and other market participants affected by COVID-19 comply with federal proxy rules for upcoming annual shareholder meetings by using technology, including virtual meetings, and the “notice-only” proxy delivery option. The SEC also issued C&DI 104.18 to clarify that in circumstances in which the filing of a definitive proxy statement is delayed, public companies may apply the Order to obtain deadline relief by filing a Form 8-K within 120 days of their year-end.

• **Manual signatures** — On March 24, 2020, the SEC staff issued a statement acknowledging that registrants may have difficulty obtaining manual signatures before filing electronically with the SEC. The statement also gives registrants certain conditional accommodations regarding such requirements in SEC Regulation S-T.

To date, the SEC has issued over 40 different statements, orders, and pieces of interpretative guidance. For more information about the above actions as well as other SEC responses to COVID-19, see the SEC’s COVID-19 Response Web site.

**PCAOB Announcement Related to COVID-19**

On March 18, 2020, the PCAOB announced updates to its operations in light of COVID-19. Changes include conducting remote inspections to the extent possible as well as cancelling in-person stakeholder events, such as audit committee and preparer roundtables, and holding virtual meetings instead. In addition, on March 23, 2020, the PCAOB announced that it would give “PCAOB-registered audit firms an up to 45-day relief period from inspections,” with certain exceptions, and that it expects “to fully resume inspections beginning May 11, 2020.”

**SEC Reporting and Disclosure Considerations**

The SEC expects registrants to clearly disclose material risks and uncertainties. As a result, most entities will need to disclose the impact of COVID-19 in various sections of their SEC filings, including the risk factors section, MD&A, the business section, legal proceedings, disclosure controls and procedures, internal control over financial reporting, and financial statements. In DG Topic 9 (issued March 25, 2020), and in a manner consistent with other guidance on evolving risks, the SEC staff provided a series of illustrative questions for registrants to consider when developing disclosures related to the current and expected future impact of COVID-19:

- How has COVID-19 impacted your financial condition and results of operations? In light of changing trends and the overall economic outlook, how do you expect COVID-19 to impact your future operating results and near-and-long term financial condition? Do you expect that COVID-19 will impact future operations differently than how it affected the current period?

- How has COVID-19 impacted your capital and financial resources, including your overall liquidity position and outlook? Has your cost of or access to capital and funding sources, such as revolving credit facilities or other sources changed, or is it reasonably likely to change? Have your sources or uses of cash otherwise been materially impacted? Is there a material uncertainty about your ongoing ability to meet the covenants of your credit agreements? If a material liquidity deficiency has been identified, what course of action has the company taken or proposed to take to remedy the deficiency? Consider the requirement to disclose known trends and uncertainties as it relates to your ability to service your debt or other financial obligations, access the debt markets, including commercial paper or other short-term financing arrangements, maturity mismatches between borrowing sources and the assets funded by those sources, changes in terms
requested by counterparties, changes in the valuation of collateral, and counterparty or customer risk. Do you expect to disclose or incur any material COVID-19-related contingencies?

- How do you expect COVID-19 to affect assets on your balance sheet and your ability to timely account for those assets? For example, will there be significant changes in judgments in determining the fair-value of assets measured in accordance with U.S GAAP or IFRS?
- Do you anticipate any material impairments (e.g., with respect to goodwill, intangible assets, long-lived assets, right of use assets, investment securities), increases in allowances for credit losses, restructuring charges, other expenses, or changes in accounting judgments that have had or are reasonably likely to have a material impact on your financial statements?
- Have COVID-19-related circumstances such as remote work arrangements adversely affected your ability to maintain operations, including financial reporting systems, internal control over financial reporting and disclosure controls and procedures? If so, what changes in your controls have occurred during the current period that materially affect or are reasonably likely to materially affect your internal control over financial reporting? What challenges do you anticipate in your ability to maintain these systems and controls?
- Have you experienced challenges in implementing your business continuity plans or do you foresee requiring material expenditures to do so? Do you face any material resource constraints in implementing these plans?
- Do you expect COVID-19 to materially affect the demand for your products or services?
- Do you anticipate a material adverse impact of COVID-19 on your supply chain or the methods used to distribute your products or services? Do you expect the anticipated impact of COVID-19 to materially change the relationship between costs and revenues?
- Will your operations be materially impacted by any constraints or other impacts on your human capital resources and productivity?
- Are travel restrictions and border closures expected to have a material impact on your ability to operate and achieve your business goals?


DG Topic 9 also provides considerations regarding how to reflect the effects of the pandemic in non-GAAP measures and key performance indicators (KPIs). The discussion below addresses many of these considerations; however, we encourage registrants to review the questions and guidance in DG Topic 9 in detail.

**Risk Factors**

Registrants must disclose information about the most significant risks facing the entity or its securities. While many registrants may already disclose their general risk related to issues such as potential natural disasters or pandemics, they should consider whether to update the disclosure to clarify that the risk is no longer hypothetical and to provide more specificity about the actual and potential future impact of COVID-19. In its Order (that provides conditional relief from filing deadlines — see discussion above), the SEC emphasized the importance of updating this disclosure and stated that a registrant must disclose “a company specific risk factor or factors explaining the impact, if material, of COVID-19 on its business.”

**MD&A**

MD&A supplements the financial statements by providing information about a registrant’s financial condition, results of operations, and liquidity. A registrant should discuss in its MD&A the material quantitative and qualitative impact of COVID-19 on its business. For example, the discussion could address potential issues such as changes in consumer behavior, including an unusual increase or decrease in demand, travel bans or limitations, store or facility closures, declines in customer traffic, the impact on distributors, increased competition for raw materials, supply chain interruptions, production delays or limitations, risk of loss on
significant contracts, liquidity challenges or debt covenant issues, regulatory risks, or the impact on human capital.

In addition to discussing the impact on historical results, registrants are also expected to disclose in accordance with SEC Regulation S-K, Item 303, “any known trends or uncertainties that have had or that the registrant reasonably expects will have a material favorable or unfavorable impact” on their financial condition, results of operations, or liquidity. These forward-looking disclosures are especially critical in connection with events such as the COVID-19 pandemic and the related economic uncertainty. Such disclosures can give investors an “early warning” about risks such as (1) when and under what conditions charges may be incurred in the future and the potential magnitude of such charges, (2) when revenue growth or profit margins may not be sustainable because of underlying economic conditions, or (3) when the registrant may be unable to comply with debt covenants or have other liquidity issues. As a result of the COVID-19 pandemic, liquidity may be significantly affected given the potential disruptions to normal levels of revenues and operating cash flows as well as to access to cash through debt or equity markets. In their MD&A disclosures about liquidity, registrants should consider discussing their working capital or other cash flow needs, anticipated changes in the amount and timing of cash generated from operations, the availability of other sources of cash along with potential limitations associated with accessing such sources, and the possible ramifications of their inability to meet their short- or long-term liquidity needs.

Early-warning disclosures should also be considered by management in connection with accounting areas that require significant judgment, such as contingencies, valuation allowances, or potential impairments. These account-specific disclosures are frequently included as part of the critical accounting estimates section of MD&A, as discussed (with respect to goodwill impairment) in Section 9510 of the SEC’s Financial Reporting Manual. Given the uncertainty associated with COVID-19, there is likely to be a substantial increase in the level of judgment entities need to apply in estimating future results and the potential range of reasonably likely outcomes. Registrants should therefore consider expanding their disclosures about (1) the key assumptions used in their most significant estimates and (2) the sensitivity of such estimates to changes that could reasonably occur as events associated with COVID-19 continue to develop. Consequently, registrants should consider updating, in their quarterly report on Form 10-Q, the critical accounting estimates previously disclosed in the Form 10-K to the extent that there have been material changes to key assumptions and estimates.

MD&A disclosures are typically included in a Form 10-K or Form 10-Q, but due to the rapidly evolving impact of COVID-19, registrants may also file current reports on Form 8-K to update investors on the current and potential future impact of COVID-19 on their business. Many of these filings have also announced that registrants are withdrawing or updating previously issued guidance related to expected 2020 revenue and earnings targets.

**Earnings Releases**

As a result of COVID-19, there may be circumstances in which complete GAAP financial information is not available at the time of an earnings release because of ongoing consideration of COVID-19-related matters. Registrants may choose to provide preliminary GAAP results that either include provisional amounts that are based on a reasonable estimate or a range of reasonably estimable GAAP results. Registrants should consider providing transparent disclosures that explain (1) why complete GAAP financial information is not available and (2) what additional information or analysis will be needed to complete it. Since earnings releases often include non-GAAP measures, registrants should consider the guidance in DG Topic 9 on the non-GAAP reconciliation requirements when complete GAAP information is not available (see the Non-GAAP Measures discussion below).
Non-GAAP Measures

Registrants may also consider reflecting various impacts of COVID-19 in their non-GAAP measures. DG Topic 9 notes that if a registrant elects to do so, “it would be appropriate to highlight why management finds the measure or metric useful and how it helps investors assess the impact of COVID-19 on the company’s financial position and results of operations.” When using non-GAAP financial measures, a registrant must be aware of certain SEC requirements, including the rules in SEC Regulation G and in SEC Regulation S-K, Item10(e). In addition, the SEC staff has published a number of compliance and disclosure interpretations, which are updated periodically, to clarify its views on many non-GAAP presentation issues. The key requirements for disclosure of non-GAAP information in SEC filings, including press releases, are related to the following:

- **Prominence** — The most directly comparable GAAP measure should be presented with equal or greater prominence.
- **Not misleading** — A non-GAAP measure should not be presented in a misleading manner.
- **Reconciliation** — Registrants should present a quantitative reconciliation of the non-GAAP measure to the most directly comparable GAAP measure and should transparently describe all adjustments. In DG Topic 9, the SEC staff stated that if complete GAAP financial information is not available at the time of an earnings release because of on-going consideration of matters related to COVID-19, the staff would not object to a registrant's reconciliation of non-GAAP financial measures to the most directly comparable *preliminary* GAAP measure that reflects either “provisional amount(s) based on a reasonable estimate, or a range of reasonably estimable GAAP results.” This position is limited solely to non-GAAP measures that have been provided to a registrant's board of directors to report financial results and does not apply to filings on Form 10-K or 10-Q. When relying on this position, a registrant “should explain, to the extent practicable, why the line item(s) or accounting is incomplete, and what additional information or analysis may be needed to complete the accounting.”
- **Clear labeling** — Registrants should clearly label and describe non-GAAP measures and adjustments but should not, for example, use titles or descriptions that are confusingly similar to those used for GAAP financial measures.
- **Usefulness and purpose** — Registrants should disclose why they believe the non-GAAP measure provides useful information to investors and, to the extent material, a statement disclosing how management uses the non-GAAP measure.

While the SEC may not object to a non-GAAP measure that adjusts for unusual items (e.g., restructuring charges), measures that adjust revenues or eliminate recurring cash operating expenses may be viewed as potentially misleading and therefore may be prohibited. Accordingly, a registrant may choose to present a non-GAAP measure that adjusts for unusual, direct, and incremental costs due to COVID-19 as well as any related economic uncertainty, such as asset or goodwill impairments. However, a non-GAAP measure that adjusts for estimated lost revenues or profits is likely to be inappropriate because the SEC may view it to be a tailored accounting principle. Entities may also consider presenting a non-GAAP measure that adjusts for salary continuation while its operations are suspended or closed. While the continuation of salaries in the absence of normal (or any) revenues may be considered unusual, adjusting for such expenses would represent the elimination of recurring cash operating expenses. Therefore, non-GAAP measures that adjust for such items may be challenged by the SEC.

Any new adjustments or changes to non-GAAP measures related to COVID-19 should be clearly labeled, and changes to such measures should be transparently disclosed. For more information, see Deloitte’s *A Roadmap to Non-GAAP Financial Measures.*
Metrics and KPIs

Many registrants disclose the metrics and KPIs used to manage their business. To provide guidance on such disclosures, the SEC issued an interpretive release that became effective on February 25, 2020. Existing metrics and KPIs may be affected by the COVID-19 pandemic, and registrants may establish new metrics related to its impact.

In a manner consistent with the non-GAAP guidance discussed above and the interpretive release, the SEC would generally expect registrants to disclose the following for all metrics and KPIs used:

- A clear definition of the metric and how it is calculated.
- A statement indicating the reasons why the metric provides useful information to investors.
- A statement indicating how management uses the metric in managing or monitoring the performance of the business.
- A description of any key estimates, assumptions, and limitations (e.g., whether the metric is a “hard” amount or an estimate).
- Presentation of the metric within a balanced discussion.

If metrics change or evolve as a result of the impact of COVID-19 or for any reason, registrants should ensure that there is clear and transparent disclosure of the change and that definitions of the affected metrics are updated accordingly. Further, to provide the appropriate context for changes to metrics, a registrant may need to recast prior periods to conform to the current presentation if the changes are significant.

Broad Financial Reporting and Accounting Considerations

Requirement to Develop Estimates, and Consistency of Assumptions and Estimates

As a result of the uncertainty associated with the unprecedented nature of the COVID-19 pandemic, entities have faced challenges related to selecting appropriate assumptions and developing reliable estimates. Nevertheless, they will still be required by U.S. GAAP to develop estimates that underly various accounting conclusions. To develop estimates, entities will need to consider all available information. They will also need to consider whether they have met all applicable disclosure requirements, including those in ASC 275.4

Further, entities may be required to use assumptions or estimates for more than one purpose (e.g., forecasted revenues or cash flows may be an assumption used in multiple impairment tests, in assessments of the realizability of deferred tax assets, and in an entity’s ability to continue as a going concern). When a single assumption is used in multiple analyses, entities should verify that the same assumption is being used in each analysis unless the guidance in U.S. GAAP permits otherwise. For example, under the CECL model, an entity is required to prepare its own reasonable and supportable forecasts, which is not necessarily consistent with a market-based fair value notion. Such consistency is particularly important for entities with multinational operations or with decentralized accounting and financial reporting functions.

---

4 ASC 275-10-50-6 requires entities to disclose “discussion of estimates when, based on known information available before the financial statements are issued or are available to be issued, . . . it is reasonably possible that the estimate will change in the near term and the effect of the change will be material.”
In addition, entities should consider external events and circumstances when assessing whether (1) the changes made in assumptions and estimates from the previous period were appropriate or (2) it was appropriate in the current period not to have updated or changed the assumptions used in the previous period.

**Impairment of Nonfinancial Assets (Including Goodwill)**

As a result of the changes in the current economic environment related to the COVID-19 pandemic, entities should consider whether they are experiencing any conditions (e.g., decreased revenues, order cancellations, supply chain disruptions, store closures, or declines in share price) that indicate that their assets should be tested for impairment. Even assets that have an annual impairment testing requirement, such as goodwill or indefinite-lived intangible assets, should be tested for impairment when a triggering event occurs. For example, the recent decline in global equity markets could lead an entity to conclude that it is required to test goodwill for impairment (because a decline in market capitalization could signal a change in facts and circumstances “that would more likely than not reduce the fair value of a reporting unit below its carrying amount,” in accordance with ASC 350-20-35-30). The guidance for testing assets for impairment varies depending on the asset being tested. Some nonfinancial assets are tested for impairment individually, while others are tested as part of a larger unit of account. Further, some nonfinancial assets are tested by using a recoverability test, while others are tested by using a fair value or net realizable value (NRV) test. The guidance for testing nonfinancial assets for impairment is summarized in the following sections.

In addition, it is important to consider the order in which assets are tested so that the entity can ensure that any required adjustments are made before including those assets in the testing of larger units of account. Assets that are not held for sale should be tested for impairment in the following order: (1) assets outside of the scope of ASC 360-10 (other than goodwill) such as inventory, capitalized costs to obtain or fulfill a revenue contract, and indefinite-lived intangible assets, (2) long-lived assets in accordance with ASC 360-10, and (3) goodwill in accordance with ASC 350-20.

**Inventory**

The COVID-19 pandemic may affect the recoverability of inventory balances. Some entities with inventories that are seasonal or are subject to expiration may have to assess whether a larger reserve for obsolescence or slow-moving stock (e.g., markdowns) may be necessary at an interim or annual period as a result of a slower sales pace. Other entities may have to assess whether a decline in their future estimated selling price has arisen, which may require a write-down in the cost of inventory in an interim or annual period. In addition, manufacturing entities may have to reassess their practices for fixed overhead cost absorption if production volumes become abnormally low during the year as a result of plant closings or lower demand for their products.

ASC 330 requires that most inventory be measured at the lower of its cost or (1) market value (for inventory measured by using last in, first out [LIFO] or the retail inventory method) or (2) NRV (for all other inventory). In a volatile economic environment, it may be particularly important for entities to determine whether the utility of their inventory on hand has been impaired. Entities should apply the guidance in ASC 330-10-35-1A through 35-11, which addresses adjustments of inventory balances to the lower of cost or market or NRV as appropriate. Interim inventory impairment losses should generally be reflected in the interim period in which they occur, with subsequent recoveries recognized as gains in future interim periods of the same annual period.

ASC 330 states that variable production overhead costs should be “allocated to each unit of production on the basis of the actual use of the production facilities” (emphasis added). It also calls for the allocation of fixed overhead costs to each manufactured item on the basis of an expectation that production facilities are running at normal production capacity, which
refers to a “range of production levels [that are] expected to be achieved over a number of periods or seasons under normal circumstances” (e.g., annual production). The COVID-19 pandemic may affect manufacturing entities in a number of ways (e.g., shortages of labor and materials or unplanned factory downtime) that, if sustained, may result in an abnormal reduction of an entity’s production levels. In those circumstances, an entity should not increase the amount of fixed overhead costs allocated to each inventory item. Rather, the unallocated fixed overhead costs are recognized in profit or loss in the period in which they are incurred.

**Costs to Obtain or Fulfill a Revenue Contract and Up-Front Payments to Customers**

An entity may have capitalized costs to obtain or fulfill a contract as an asset in accordance with ASC 340-40-25-1 or ASC 340-40-25-5, respectively. ASC 340-40-35-1 through 35-6 provide guidance on determining the appropriate amortization period and on recognizing any impairment loss on such an asset. An entity may need to update its amortization approach to reflect any significant changes in the expected timing of the transfer of the related goods or services. In addition, an entity must recognize an impairment charge if the carrying amount of the asset exceeds (1) the sum of the amount of consideration expected to be received and the amount of consideration already received but not yet recognized as revenue less (2) the costs that are directly related to providing the remaining promised goods or services under the contract that have not been recognized as expenses. The consideration determined in (1) above should be adjusted to account for the customer’s credit risk, and the amounts determined under both (1) and (2) should include the effects of expected contract renewals from the same customer. An entity may also need to consider whether contract modifications or changes in expectations regarding customer renewals affect the amortization or recoverability of these revenue-related costs.

An entity may also have capitalized up-front payments to customers that are reflected as a reduction in the transaction price. We believe that the entity should perform similar analyses for any asset recognized for such up-front payments.

Further, an entity should evaluate contract assets for impairment by using the same model as customer receivables. See the Financial Instruments and Contract Assets discussion for more information.

**Indefinite-Lived Intangible Assets Other Than Goodwill**

As stated in ASC 350-30-35-4, an indefinite-lived intangible asset is one for which “there is no foreseeable limit on the period of time over which it is expected to contribute to the cash flows of the reporting entity.” Certain brands, trademarks, or licenses (such as FCC licenses) are common examples.

Indefinite-lived intangible assets are tested annually for impairment and more frequently if an event or a change in circumstances indicates that it is more likely than not that the intangible asset is impaired in accordance with ASC 350-30. ASC 350-30-35-18B provides examples of these events or changes in circumstances, which include, but are not limited to, financial performance, legal or political factors, entity-specific events, and industry or market considerations. On the basis of this assessment, if an entity determines that it is more likely than not that the carrying value of the intangible asset exceeds its fair value, the entity performs a valuation to determine the fair value of the asset and recognizes an impairment loss equal to the excess of the carrying amount of the intangible asset over its fair value.

A valuation technique that is often applied to the measurement of a brand or trademark is the relief from royalty method. The relief from royalty method, which focuses primarily on expected revenues and royalty rates, requires the entity to make fewer assumptions than other income methods. However, an entity may find it challenging to project revenues
because of the pandemic’s unique impact not only on consumer buying decisions but also on the entity’s ability to continue to (1) produce products in the event of supply chain disruptions or (2) deliver services in the event of shelter in place or work at home requirements, for example. Entities are expected to use their best estimate of all required business and valuation assumptions for this or other income methods used to measure the fair value of an indefinite-lived intangible asset.

In addition to evaluating the need for an interim impairment test, an entity should also consider whether there are any indicators that an intangible asset classified as indefinite-lived has become finite-lived, which might occur if an entity changes its expected use of the asset in response to the effects of the COVID-19 pandemic.

**Long-Lived Assets**

An entity should consider whether it is experiencing (1) a decline in revenues, (2) an increase in costs (i.e., a decline in net cash flows), or (3) both as a result of the COVID-19 pandemic. Such changes may indicate that the entity should test its long-lived assets for recoverability. Although we expect each entity to be affected differently both in terms of the effects of the COVID-19 pandemic on its cash flows and on the susceptibility of its long-lived assets to impairment, an entity should document its considerations regarding the recoverability of its long-lived assets.

Entities are required by ASC 360-10-35-21 to test a long-lived asset (asset group) that is classified as held and used for recoverability “whenever events or changes in circumstances indicate that its carrying amount may not be recoverable” (e.g., a significant adverse change in the business climate that could affect the value of a long-lived asset [asset group]). Events or changes in circumstances that prompt a recoverability test are commonly referred to as “triggering events.” In light of events such as store closures or idling of manufacturing facilities, or trends related to decreases in consumer spending, many entities are likely to experience one or more of the triggering events listed in ASC 360-10-35-21. For example, triggering events that may be present as a result of the COVID-19 pandemic include, but are not limited to, a “significant decrease in the market price of a long-lived asset (asset group),” a “significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition,” or a “current-period operating or cash flow loss combined with . . . a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group).”

ASC 360-10-35-23 states that “a long-lived asset or assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.” Such a combination is called an asset group.

An asset group may include not only long-lived assets that are within the scope of ASC 360-10 but also other assets such as receivables, inventory, indefinite-lived intangible assets, or goodwill. ASC 360-10-15-5 provides a list of assets that are not in the scope of ASC 360-10. Note that ASC 360-10 applies to long-lived assets that are not in the scope of other GAAP, such as property, plant, and equipment (PP&E); finite-lived intangible assets (customer relationships, technology, brands, and tradenames); and right-of-use assets.

To test a long-lived asset (asset group) for recoverability, an entity compares the carrying value of the asset (asset group) to the undiscounted net cash flows generated from the asset’s (asset group’s) use and eventual disposal. While the use of undiscounted cash flows generally indicates that a long-lived asset (asset group) is less prone to impairment, reductions in the estimates of undiscounted cash flows based on the expected duration and magnitude of the COVID-19 pandemic may indicate that the long-lived asset (asset group) is not recoverable.
If an entity estimates future cash flows to test the recoverability of a long-lived asset (asset group), such an estimate should include only the future cash flows (cash inflows minus associated cash outflows) that are (1) directly associated with the asset (asset group) and (2) expected to arise as a direct result of the use and eventual disposition of the asset (asset group). To estimate future cash flows, the entity must consider both cash inflows and cash outflows. ASC 360 indicates that it may be useful for the entity to apply a probability-weighted approach when it is considering alternative courses of action to recover the carrying amount of a long-lived asset (asset group). Such an approach may also be beneficial when the entity is considering alternative courses of action to manage cash outflows in response to anticipated revenue declines as well as when evaluating the extent of government intervention and the potential effects of any such intervention on both cash inflows and cash outflows.

ASC 360-10-35-30 states that the “assumptions used in developing [cash flow estimates should] be reasonable in relation to the assumptions used in developing other information used by the entity for comparable periods, such as internal budgets and projections, accruals related to incentive compensation plans, or information communicated to others.”

If the entity determines that the carrying amount of the long-lived asset (asset group) is not recoverable, the entity then performs the next step in the impairment test by recognizing an impairment loss for the amount by which the carrying amount of the long-lived asset (asset group) exceeds its fair value. It then allocates that amount to the long-lived assets that are in the scope of ASC 360-10 “on a pro rata basis using the relative carrying amounts of those assets, except that the loss allocated to an individual long-lived asset of the group shall not reduce the carrying amount of that asset below its fair value whenever that fair value is determinable without undue cost and effort.”

If an entity determines that a long-lived asset (asset group) is recoverable, it does not recognize an impairment loss, even if the carrying value of that asset (asset group) exceeds its fair value. Regardless of whether an entity recognizes an impairment loss, it should still consider whether the existence of a trigger indicates that there has been a change in the useful life or salvage value of its long-lived assets. If so, it should revise its depreciation or amortization estimates accordingly.

Sometimes, an entity may conclude that the affected long-lived assets will be sold, abandoned, or otherwise disposed of. Under ASC 360, if the held-for-sale criteria in ASC 360-10-45-9 are met, the entity is required to measure the asset (asset group) “at the lower of its carrying amount or [its] fair value less cost to sell” in accordance with ASC 360-10-35-43. A long-lived asset that will be abandoned will continue to be classified as held and used until it is disposed of. Such an asset is disposed of when it ceases to be used. However, a “long-lived asset that [is] temporarily idled shall not be accounted for as if abandoned” in accordance with ASC 360-10-35-49. Further, when “a long-lived asset ceases to be used, the carrying amount of the asset should equal its salvage value, if any.”

**Leases (ASC 842) — Right-of-Use Assets**

Impairments to right-of-use (ROU) assets could occur as a result of business closures, supply chain disruption, or other consequences of the pandemic that negatively affect the future cash flows expected to be derived from the use of the underlying PP&E.

ROU assets are subject to the impairment and disposal guidance in ASC 360; therefore, a lessee must test its ROU assets for impairment in a manner consistent with the treatment of other long-lived assets. In accordance with ASC 842-20-35-9, a “lessee shall determine whether a right-of-use asset is impaired and shall recognize any impairment loss in accordance with Section 360-10-35 on impairment or disposal of long-lived assets.” Therefore, the impairment analysis of ROU assets would be included as part of the analysis discussed above for long-lived assets that are held and used.
In accordance with ASC 842-20-35-10, an impaired ROU asset should be subsequently measured at its carrying amount (after the impairment) less any accumulated amortization. Subsequent amortization of the ROU asset (for both operating and finance leases) would be on a straight-line basis unless another systematic basis is more representative of the pattern over which the lessee expects to consume the remaining economic benefits of the right to use the underlying asset.

For more information, see Q&A 8-12, Considerations Related to the Impairment of an ROU Asset, in Deloitte’s A Roadmap to Applying the New Leasing Standard.

**Goodwill**

As a result of the effects of the COVID-19 pandemic, we expect more entities to conclude that there is a requirement to test the goodwill of one or more reporting units for impairment between annual testing dates. For many entities, recoverability of goodwill balances has not been a heightened concern in recent years because of overall favorable economic conditions. Specifically, until recently, the market capitalization of many publicly reporting entities has been in excess of their carrying amounts as measured by net assets. Such excesses may no longer exist for some entities because of recent dramatic declines in equity markets.

Under ASC 350-20-35-28 through 35-30, an entity is required to test goodwill for impairment at the reporting-unit level at least annually or “between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.” ASC 350-20-35-3C provides examples of events and circumstances that may meet such a threshold and hence necessitate the testing of goodwill for impairment between annual tests. These include “a deterioration in general economic conditions,” “a deterioration in the environment in which an entity operates,” “a change in the market for an entity’s products or services,” “[o]verall financial performance such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods,” and, “[i]f applicable, a sustained decrease in share price (consider in both absolute terms and relative to peers).”

A reporting unit with only a small cushion (excess of fair value over carrying amount) at the time of its most recent quantitative test is generally more susceptible to impairment, which may have been noted in prior disclosures related to goodwill of reporting units at higher risk for impairment.

An entity may choose to qualitatively evaluate relevant events or circumstances to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Alternatively, an entity may skip the qualitative assessment and proceed directly to step 1 of the goodwill impairment test. In step 1 of the test, the entity compares the reporting unit’s carrying amount, including goodwill, with its fair value and recognizes an impairment loss for any excess.

In January 2017, the FASB issued ASU 2017-04, which eliminated step 2 of the goodwill impairment test and the requirement to calculate the implied fair value of goodwill. While that ASU is not yet effective for all entities (e.g., private companies and not-for-profit entities), many entities have elected to early adopt its provisions.

When performing a quantitative test, an entity must develop certain business and valuation assumptions. If the entity is using an income approach when performing its fair value measurements, the entity must apply judgment when developing its prospective financial information because of the unique nature of the COVID-19 pandemic and the resulting impacts on government, business, and consumer decisions. The entity is expected to use its best estimates of those business and valuation assumptions. In addition, if the entity is using

---

5 FASB Accounting Standards Update (ASU) No. 2017-04, Simplifying the Test for Goodwill Impairment.
a market approach when performing its fair value measurements, the entity may encounter challenges in the current environment related to identifying the appropriate multiples and transactions to use. Consultation with valuation specialists may be warranted.

When performing a quantitative test for impairment, a publicly traded entity with multiple reporting units generally assesses the reasonableness of the resulting implied control premium as measured by the percent by which the aggregate sum of the fair values of its reporting units exceeds the entity’s market capitalization. Such a comparison is not required by U.S. GAAP and may be more difficult to perform in the current environment because of market volatility. However, the comparison can continue to yield useful information about the reasonableness of the underlying reporting unit’s fair value measurements. In cases of market volatility, an entity may need to apply judgment in determining the market capitalization to use in the comparison.

ASC 350 provides an accounting alternative for the subsequent measurement of goodwill for private companies and not-for-profit entities. While certain differences exist for entities adopting the accounting alternative, such entities are required to test goodwill for impairment when a triggering event occurs.

Financial Instruments and Contract Assets

Impairment and Valuation Considerations

As a result of the pandemic, entities may need to assess their investments and loans for impairment. Investments that may be affected include equity securities and private debt and, in certain instances, investments in sovereign debt. Moreover, the COVID-19 pandemic may cause additional volatility in the global markets, which has affected the fair values of investments (e.g., credit spreads may widen or the creditworthiness of counterparties may be affected).

The following guidance applies to investments in equity securities that are not accounted for at fair value with changes in fair value recognized in earnings:

- **Equity securities without readily determinable fair values** — ASC 321-10-35-3 and 35-4 address the subsequent measurement of equity securities without readily determinable fair values that are accounted for by using the measurement alternative described in ASC 321-10-35-2. ASC 321-10-35-3 states, in part, that “[a]n equity security . . . measured in accordance with paragraph 321-10-35-2 shall be written down to its fair value if a qualitative assessment indicates that the investment is impaired and the fair value of the investment is less than its carrying value.”

ASC 321-10-35-4 further states that for such an impaired equity security, “an entity shall include an impairment loss in net income equal to the difference between the fair value of the investment and its carrying amount.” Because the fair value of such an investment is not readily determinable, the entity will need to estimate the fair value under ASC 820 to measure the amount of the impairment loss. Once an investment in an equity security that is measured under ASC 321-10-35-2 is impaired, the entity cannot recognize a recovery in the investment’s fair value in the absence of an observable price change for an identical or a similar security, as discussed in ASC 321-10-35-2.

ASC 321-10-35-3 requires entities to perform a qualitative assessment in each financial reporting period to evaluate whether equity securities accounted for under the measurement alternative in ASC 321-10-35-2 are impaired. That qualitative assessment is performed on the basis of the impairment indicators in ASC 321-10-35-3. Entities should note that ASC 321-10-35-3(c) applies particularly to the COVID-19 impacts; it states, in part, that one indicator of impairment is “[a] significant adverse change in the general market condition of either the geographical area or the industry...
in which the investee operates.” This impairment indicator will often be met as a result of significant declines in equity prices globally that have occurred as a result of the COVID-19 pandemic.

In the evaluation of an equity security for impairment, neither the significance of the impairment amount nor the impairment's duration is relevant. Although the fair value of nonmarketable equity securities may be difficult to measure because of the unobservability of inputs, entities that have investments whose fair values have been affected by the pandemic must make a reasonable estimate of fair value when recognizing impairment losses. Such impairment losses must be recognized for declines in fair value below the carrying amount even if the investor believes that such declines are temporary in nature. In addition to evaluating and recognizing an impairment, an entity would write down the carrying amount of an equity security that is accounted for by using the measurement alternative in ASC 321-10-35-2 if an observable price change in an identical or a similar security reflects a fair value that is below the investment’s previously recorded carrying amount.

To assess and measure impairment losses, entities that have a significant number of equity securities that are accounted for by using the measurement alternative described in ASC 321-10-35-2 will need to stratify (or group) investments into those that share similar attributes. Factors to consider include, but are not limited to:

- **Any appreciation in fair value since the original acquisition of the investment that has not been recognized as a remeasurement event (i.e., the investment must be remeasured at fair value if the entity observes a transaction in the same or similar security)** — For example, some investments may represent “seed money” investments that were made when the fair value of the investee's equity was relatively low. In these situations, there may have been a significant increase in fair value during the recent bull market. Thus, investors may be able to determine, without having to apply significant judgment, that although the fair value of such investments has declined recently as a result of the impact that COVID-19 has had on stock markets, there is still a sufficient “cushion” between the fair value and carrying amount so that an impairment loss has not been incurred.

- **The industry in which the investee entity operates** — Some industries have performed relatively well since the onset of the pandemic. For example, certain companies that provide teleconferencing services, food and other delivery services, cleaning and other health supplies, pharmaceutical solutions, and other technology solutions have outperformed other stocks generally. An investee that operates in a sector that has performed relatively well during the pandemic may be less susceptible to material impairment losses; however, in such a scenario, specific consideration is required and the impairment determination may depend on the fundamentals applicable to the investee. Other companies, such as airlines and other travel-related entities, have been severely affected and thus have a higher risk of material impairment losses.

- **The geographic location of the investee entity** — Although COVID-19 has generally resulted in declines in stock prices globally, the significance of those declines has varied among different regions. Thus, if an entity has investments in nonmarketable equity securities in geographic locations that have not experienced price declines that are as significant as those in other areas, those investments may be less susceptible to impairment losses.

- **The size of the investee entity** — Since the start of the pandemic, the performance of small-cap equities has generally been poorer in the United States than that of other equities. Thus, investments in smaller companies may be considered to have been more significantly affected by COVID-19.
• **The quantitative significance of the investee entity** — Entities that have numerous investments may “scope” the evaluation in a manner that focuses on those investments that are of a magnitude such that impairment losses could be material. For example, an entity may determine that there is a population of investee entities whose carrying amount, in the aggregate, is inconsequential. Since the maximum potential impairment loss cannot exceed the carrying amount, the entity may decide to focus only on investments that individually or in the aggregate could have material impairment losses.

• **Other factors specific to the investee entity** — An investor may be aware of specific information that positively or negatively affects an individual investee. For example, an investee with nonpublicly traded equity securities may have issued announcements to the public that reflect either the positive or negative impacts of the pandemic. In addition, some investees may have other publicly traded securities such as bonds or convertible instruments. Entities may find observable pricing information pertaining to such other investments to be useful in evaluating impairment losses.

• **Liquidity risk premiums** — Entities should keep in mind that the fair value of an illiquid equity investment could be more significantly affected by the COVID-19 outbreak than a readily tradable equity security. Thus, in determining fair value, entities should take into account the need to reconsider any nonmarketability discount applied in the estimation of fair value.

Entities should consider disclosing significant judgments made in the estimation of impairment losses on equity investments that are accounted for by using the measurement alternative in ASC 321-10-35-2.

• **Investments in equity method investments and joint ventures** — Entities with equity method investments or joint ventures that are adversely affected by the economic uncertainty in the affected regions may need to evaluate whether decreases in an investment’s value are other than temporary. For these investments, ASC 323-10-35-31 requires the recognition of a loss that is other than temporary even if such a decrease in value is greater than what would otherwise be recognized if the equity method were applied. As indicated in ASC 323-10-35-32, “[e]vidence of a loss in value might include [a lack of] ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.” Further, ASC 323-10-35-32 states that a “current fair value of an investment that is less than its carrying amount may indicate a loss in value of the investment.”

Note that in the determination of whether there is an impairment loss that should be recognized, many of the considerations relevant to nonmarketable equity securities that are accounted for by using the measurement alternative in ASC 321-10-35-2 may be relevant. However, unlike the impairment guidance applicable to investments accounted for under ASC 321-10-35-2, an impairment loss on an equity method investee is recognized only if it is other than temporary in nature. Therefore, equity method investors must apply judgments regarding the severity and duration of any decline in fair value before recognizing impairment losses on equity method investees. In many cases, those judgments are influenced by the reason for the investment (e.g., strategic vs. financial). Entities should consider disclosing significant judgments made in the evaluation of other-than-temporary impairment of equity method investees.
If an entity (1) accounts for its share of equity method investment earnings and losses by using a time lag on the basis of the guidance in ASC 323-10-35-6 and (2) determines that it should recognize an impairment loss for its equity method investment, the entity should measure and recognize the fair value of the equity method investment as of the date of the other-than-temporary impairment and not use a lag (i.e., to recognize and measure an impairment for its equity method investment, the entity should not use a lag in a manner consistent with how it records its share of earnings and losses). [Paragraph added April 13, 2020]

The impairment model applied under U.S. GAAP to financial assets other than equity investments depends on the investment’s classification and whether the entity has adopted ASC 326. The following guidance applies to entities that have not yet adopted ASC 326:

- **Available-for-sale (AFS) and held-to-maturity (HTM) debt securities** — Under ASC 320-10-35, the impairment of a debt security is considered other than temporary if the entity intends to sell the security as of the measurement date or has determined that it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. Further, an other-than-temporary impairment is considered to have occurred if (1) the entity does not intend to sell the security, (2) it is not more likely than not that the entity will be required to sell the security before recovering its amortized cost basis, and (3) the entity does not expect to recover the entire amortized cost basis of the debt security (i.e., a credit loss is considered to have occurred).

In determining the amount of impairment loss to recognize, entities should refer to the guidance in ASC 320-10-35-34B through 35-34D and ASC 320-10-35-33D. As a result of the COVID-19 pandemic, an entity may need to recognize an impairment loss if it (1) has determined that sales of AFS debt securities are inevitable because it must replenish cash and other capital resources that have been expended and (2) has not generated sufficient replacement cash flows (e.g., an entity could determine that it is more likely than not that it would be required to sell AFS debt securities). In addition, entities should be mindful that, in determining credit losses, credit rating agencies are often slow to reflect credit rating downgrades (e.g., a large number of investment-grade debt securities may already reflect negative attributes that suggest they are no longer of investment grade). Entities therefore should consider credit losses that exist as of the balance sheet date that are not yet reflected in credit ratings. An entity may evaluate bond credit spreads and other fixed-income market indicators in making such assessments.

- **Loans** — Creditors that lend to entities that may be adversely affected by economic instability resulting from the pandemic will need to assess whether certain events (such as downgrades in borrower credit ratings or declines in cash flows and liquidity) indicate that an impairment evaluation is required. The economic uncertainty could also result in loan modifications that must be accounted for as a troubled debt restructuring (TDR) in accordance with ASC 310-40. For entities that have not yet adopted ASC 326, a modification is not accounted for as a TDR before the date the modification has occurred (i.e., a legally binding agreement is in place). Nevertheless, even before the occurrence of such a modification, entities should consider the impact on incurred losses that results from changes in credit risk related to borrowers for which modifications may occur.

- **Receivables** — Receivables from entities may need to be evaluated for collectibility in accordance with ASC 310. Entities should pay particular attention to the assessment of recoverability when receivables are overdue, even if the entities have the right to charge interest for late payment. Entities should also evaluate receivables from customers in geographic regions that are most affected by COVID-19 even if those receivables are not yet past due. Entities may incur additional write-offs of receivables
deemed uncollectible or may be required to establish additional reserves on receivables due from entities that are affected (or expected to be affected) by the impacts of COVID-19.

- **Contract assets** — As is the case with receivables, entities that have contract assets will need to evaluate recorded amounts for impairment in accordance with ASC 310 by assessing the customer’s ability to pay amounts when due. The customer’s ability to pay may be adversely affected by the economic instability resulting from the impacts of COVID-19.

- **Net investments in sales-type or direct financing leases** — Lessors that have entered into sales-type or direct financing leases should evaluate their net investments in leases in accordance with ASC 842-30-35-3 (which requires any loss allowance to be recorded as indicated in ASC 310). This evaluation should take into consideration changes in both (1) the credit risk of the lessee and (2) the cash flows expected to be derived from the underlying leased property at the end of the lease. Such changes include, for example, potential cash flows from the sale of the property at the end of the lease or from renewals with the same lessee. Therefore, a deterioration in market conditions may lead to a decline in the leased asset’s value, resulting in an impairment of the net investment in the lease even if the lessee’s credit quality has not deteriorated.

Entities that have adopted ASC 326 must apply the current expected credit loss (CECL) impairment model to recognize credit losses on financial assets with contractual cash flows that are carried at amortized cost (including HTM debt securities), net investments in leases (except for operating lease receivables), reinsurance receivables, and off-balance-sheet credit exposures. Since the CECL model is based on expected losses rather than incurred losses, an allowance for credit losses under ASC 326-20 reflects (1) a risk of loss (even if remote) and (2) losses that are expected over the contractual life of the asset.

**Connecting the Dots**

As the FASB clarified in ASU 2018-19, operating lease receivables are not within the scope of CECL, although net investments in sales-type and direct financing leases are within the scope of ASC 326. An entity would need to apply other guidance — namely ASC 842 — to evaluate the impairment implications associated with operating lease receivables. For more information, see Deloitte’s July 1, 2019, Financial Reporting Alert on assessing the collectibility of operating lease receivables.

The allowance takes into account historical loss experience, current conditions, and reasonable and supportable forecasts. Because the CECL model does not specify a threshold for recognizing an impairment allowance, entities should assess the current and expected future adverse effects of a pandemic and incorporate such effects into their estimate of expected credit losses on each reporting date. They should also “evaluate whether a financial asset in a pool continues to exhibit similar risk characteristics with other financial assets in the pool” in accordance with ASC 326-20-35-2 or whether the risk characteristics of the financial asset have been affected by COVID-19 so that the asset should be removed from its current pool and either (1) moved into a different pool or (2) evaluated individually if it no longer shares risk characteristics with any other financial assets.

In some cases, entities that have adopted ASC 326 may decide to shorten the reasonable and supportable forecast period for certain portfolios because of the forecast uncertainty that results from the pandemic. In these situations, entities should also reevaluate both the reversion period and the historical loss data used for reversion purposes. For example, when an entity shortens the reasonable and supportable forecast period, it would most likely also increase the reversion period. Furthermore, depending on the remaining contractual maturity of the portfolio, it may further determine that the historical loss information used in the post-

---

reversion period should reflect losses incurred during a volatile economic environment (as opposed to long-term loss data over an entire economic cycle).

**Connecting the Dots**

For entities adopting ASC 326 as of January 1, 2020, we generally do not believe that the recent events related to COVID-19 (e.g., failure of containment, subsequent spread, declaration of a global pandemic, and severity of the impact on global economics) were known or knowable as of the transition date. Therefore, it would not be appropriate to use hindsight in determining the ASC 326 transition adjustment. Developments after January 1, 2020, would be considered in the first quarter of adoption, with any change in estimate affecting the income statement.

Under ASC 326-30, an entity also uses an allowance approach when recognizing expected credit losses on an AFS debt security. ASC 326-30-35-3 requires an entity to recognize as an allowance an AFS debt security's expected credit losses, limited by the difference between the security's fair value and its amortized cost basis. Any changes in the allowance for expected credit losses on an AFS debt security would be recognized as an adjustment to the entity's credit loss expense. ASC 326-30-55-1 lists numerous factors that an entity should consider in determining whether a credit loss exists, including adverse financial conditions. While an allowance model is applied for entities that have adopted ASC 326-30, the factors and approach used to measure credit losses are generally unchanged (see the discussion above of AFS and HTM debt securities).

The sections below discuss fair value measurement and disclosure considerations that may be relevant to impairment assessments.

**Transfers/Sales of HTM Investments**

[Updated April 13, 2020]

An entity holding HTM investments issued by entities that may be adversely affected by the economic uncertainty associated with COVID-19 may choose to transfer such investments out of the HTM classification or sell them. A decision to transfer or sell an HTM investment could call into question or “taint” the entity's intent to hold other investments in its HTM portfolios in the future unless the sale or transfer qualifies for one of the limited exceptions in ASC 320-10-25. Therefore, an entity will need to carefully evaluate whether its sales or transfers of HTM investments meet one of those exceptions.

For example, ASC 320-10-25-6(a) states that if there is evidence of a significant deterioration in the issuer’s creditworthiness, an investor’s decision to change its intent to hold that security would not be inconsistent with its original classification decision (i.e., it would not taint the remaining HTM portfolio). In addition, ASC 320-10-25-9 specifies that events that are isolated, nonrecurring, and unusual for the entity and that could not be reasonably anticipated may cause the entity to sell or transfer an HTM debt security without necessarily calling into question the entity's intent to hold other HTM debt securities to maturity. An entity's belief that it meets the conditions in ASC 320-10-35-9 because of the impacts of COVID-19, along with its decision to transfer or sell HTM securities on more than one occasion, would be inconsistent with the notion that the events are isolated and nonrecurring. For example, an entity cannot transfer some securities out of HTM in March and then also decide to transfer more securities out of HTM in June without calling into question its intent to hold its remaining HTM portfolio.
Transfers of Investments Into or Out of Trading Classification

[Added April 13, 2020]

As a result of the economic uncertainty associated with COVID-19, an entity holding debt securities classified as trading may change the way it manages those securities. For example, a financial institution may decide that it needs to use certain debt securities in its trading portfolio as collateral for borrowing under various programs, including federal lending programs. ASC 320-10-35-12 states that “given the nature of a trading security, transfers into or from the trading category . . . should be rare.” In a manner similar to transfers or sales out of the HTM portfolio (discussed above), we believe that the current economic environment may result in a rare circumstance in which an entity may reclassify securities out of the trading portfolio. However, we believe that transfers of securities out of the trading portfolio on more than one occasion for the same reason (e.g., because of the impacts of COVID-19) would not be consistent with the notion that such transfers are “rare.”

Further, we believe that transfers of securities into the trading category would not be allowed. A transfer into that category would result in immediate recognition of any previously unrealized gain or loss at the time of transfer, and securities that an entity intends to sell in the short term can be classified as AFS.

Classification of Current and Noncurrent Financial Liabilities

Liabilities are generally classified as current in an entity's balance sheet if they are reasonably expected to be settled by the entity within 12 months of the end of the reporting period (see ASC 210-10-45-5 through 45-12 for additional discussion). Unstable trading conditions in affected regions may increase the risk that entities breach financial covenants (e.g., fail to achieve a specified level of profits or interest coverage). If such a breach occurs on or before the end of the reporting period and gives the lender the right to demand repayment within 12 months of the end of the reporting period, the liability would generally be classified as current in the borrower's financial statements.

Renegotiation of Financial Liabilities

An increase in the number of entities experiencing financial difficulty because of events associated with the pandemic may lead to a greater number of debt restructurings (e.g., to extend a maturity, reduce a coupon rate, or ease covenant terms). Under ASC 470-50-40, a borrower must assess whether such a restructuring results in a substantially different instrument, in which case the modification is accounted for as an extinguishment of the original liability and the recognition of a new liability. ASC 470-60 provides guidance on whether a debtor should account for a debt restructuring as a TDR.

Impact on Hedge Accounting

The COVID-19 pandemic could significantly affect both (1) the ability of entities to apply hedge accounting under ASC 815 and (2) the earnings impact of hedge accounting. Entities should consider the following:

- Whether the occurrence of forecasted transactions remains probable within the period specified in the hedge designation documentation — For example, an entity could change its intent to make purchases or sales or may no longer have the intent or ability to roll over debt given its financial difficulties or general economic difficulties associated with the pandemic. Also, the ability of counterparties and customers to buy from or lend to the reporting entity may be adversely affected, which could limit the entity's ability to hedge certain transactions. For instance, an entity's ability to hedge probable sales to customers or probable interest payments on a loan issued by a bank may be questionable if those counterparties might be unable to perform in the current...
economic environment. As a result of these changes in facts and circumstances, an entity may be required to discontinue cash flow hedging. A delay in the occurrence of a forecasted transaction beyond the period identified in the hedge designation documentation would also require discontinuance of cash flow hedging. ASC 815-30-40-4 requires an entity to reclassify into earnings any amounts that were previously accumulated as other comprehensive income if it is probable that the forecasted transactions will not occur within two months of the period identified in the hedge designation documentation. However, that requirement does not apply in situations in which it is probable that the transaction will still occur with a delay of more than two months after the period identified in the hedge designation documentation if the delay is caused by “the existence of extenuating circumstances that are related to the nature of the forecasted transaction and are outside the control or influence of the reporting entity.” At the FASB’s April 8, 2020, meeting, the FASB staff stated that it believes that the guidance above (i.e., on delays of a forecasted transaction caused by extenuating circumstances that are related to the nature of the forecasted transaction and that are outside the control or influence of the entity) may be applied to delays in the timing of the forecasted transactions if those delays are attributable to COVID-19.

[Paragraph updated April 13, 2020]

• **The effect of any impairment on the assessment of hedge effectiveness** — For example, the cash flows of a receivable or debt security that is hedged for interest rate risk or foreign currency risk should not be included in the hedge effectiveness assessment if they are not expected to be recovered. Entities should also carefully consider the impact of credit risk and liquidity risk on hedge effectiveness since both can be a source of hedge ineffectiveness that can cause a hedge to not be highly effective. The impact could be particularly significant on entities that have uncollateralized hedging instruments with financial institutions domiciled in affected countries (since the instruments’ fair values could be significantly influenced by changes in the institutions’ credit risk).

• **Whether hedging relationships in which qualitative assessment of effectiveness is being applied require a new quantitative assessment to ensure that the hedging relationship remains highly effective** — For example, if an entity is hedging the interest rate risk in a variable-rate debt instrument with an interest rate swap, and there is a floor on the variable rate in either the debt instrument or the derivative, but not in both. As interest rates continue to decline, this could have a significant impact on the assessment of hedge effectiveness.

• **Entities should consider the risk of counterparty default with respect to their derivative and hedging portfolios** — In accordance with ASC 815-20-35-15, if it is no longer probable that the counterparty will not default, the hedging relationship ceases to qualify for hedge accounting because it is no longer expected to be highly effective.

**NPNS Election for Contracts That Meet the Definition of a Derivative**

Among other criteria, for an entity to apply the normal purchases and normal sales (NPNS) scope exception in ASC 815 to a contract, the entity must be able to assert that it is probable that the contract will not net settle and will result in physical delivery both (1) at inception and (2) throughout the contract’s term. Since the impacts of COVID-19 may call into question whether contracts with affected entities will physically settle, it might become more difficult for an entity to assert that such contracts meet the criteria for the NPNS election.

**Fair Value Measurement and Disclosures**

ASC 820 emphasizes that fair value is a market-based measurement based on an exit price notion and is not entity-specific. Therefore, a fair value measurement must be determined on the basis of the assumptions that market participants would use in pricing an asset or
liability, whether those assumptions are observable or unobservable. The fair value hierarchy in ASC 820 serves as a basis for considering market-participant assumptions and distinguishes between (1) market-participant assumptions developed on the basis of market data that are independent of the entity (observable inputs) and (2) an entity's own assumptions about market-participant assumptions developed on the basis of the best information available in the particular circumstances, including assumptions about risk inherent in inputs or valuation techniques (unobservable inputs). In accordance with the fair value hierarchy, entities are required to maximize the use of relevant observable inputs and minimize the use of unobservable inputs. This focus on the observability of inputs also often affects the valuation technique used to measure fair value.

Even in times of extreme market volatility, entities cannot ignore observable market prices on the measurement date unless they are able to determine that the transactions underlying those prices are not orderly. In accordance with ASC 820-10-35-54I, in determining whether a transaction is orderly (and thus whether it meets the fair value objective described in ASC 820-10-35-54G), an entity cannot assume that an entire market is “distressed” (i.e., that all transactions in the market are forced or distressed transactions) and place less weight on observable transaction prices in measuring fair value. See Section 10.7 of Deloitte's A Roadmap to Fair Value Measurements and Disclosures (Including the Fair Value Option) for more information about identifying transactions that are not orderly. At the FASB's April 8, 2020, meeting, the FASB staff reiterated that an entity would apply the guidance on orderly transactions discussed above. [Paragraph updated April 13, 2020]

In addition to considering whether observable transactions are orderly, entities should take into account the following valuation matters that could be significantly affected by COVID-19:

- An evaluation of the inputs used in a valuation technique and, in particular, the need to include the current market assessment of credit risk (both counterparty and own credit risk) and liquidity risk, both for derivative and nonderivative instruments. This may also involve the need to change valuation techniques or to calibrate valuation techniques to relevant transactions.
- An assessment of whether an entity can rely on data from brokers and independent pricing services when determining fair value.

The disclosures required under ASC 820 are extensive, particularly those about fair value measurements involving significant unobservable inputs (i.e., Level 3). An entity may need to consider whether the impacts of COVID-19 would affect a financial instrument's level in the fair value hierarchy (e.g., a financial instrument previously classified in Level 2 would need to be transferred to Level 3 if the fair value consists of significant unobservable inputs). ASC 820 also requires an entity to (1) describe the valuation techniques and inputs used to determine fair values (by class of financial assets and liabilities) and (2) disclose a change in a valuation technique and the reason for that change.

**Earnings per Share**

When a contract on an entity's own equity may be settled in cash or common stock, share settlement is presumed for the diluted earnings per share (EPS) accounting in accordance with ASC 260-10-45-45. However, as discussed in ASC 260-10-55-32, if an entity (1) controls the ability to settle the contract in cash and (2) demonstrates its intent to settle the contract in cash, it may overcome the presumption of share settlement. In these situations, the entity may be required to adjust the numerator in the calculation of diluted EPS but would not include any incremental shares in the denominator of the diluted EPS calculation. For example, entities often make an assertion about the ability and intent to cash settle certain convertible debt instruments that may be settled in any combination of cash or shares at the entity's election.
In times of economic stress, entities may need to conserve cash resources. Consequently, it may no longer be appropriate to overcome the presumption of share settlement for contracts that may be settled in cash or stock because the entity fails to continue to have the ability or intent to cash settle such contracts.

**Revenue Contracts With Customers**

As a result of business disruptions associated with the COVID-19 pandemic, an entity may be prevented from entering into customer agreements through its normal business practices, which may make the determination of whether it has enforceable rights and obligations challenging. In addition, because many of its customers are experiencing financial difficulties and liquidity issues, an entity may need to develop additional procedures to properly assess the collectibility of its customer arrangements and consider changes in estimates related to variable consideration (e.g., because of greater returns, reduced usage of its products or services, or decreased royalties). To help its customers or to provide incentives for them to continue purchasing its goods or services, the entity may (1) revise its agreements to reduce any purchase commitments; (2) allow customers to terminate agreements without penalty; or (3) provide price concessions, discounts on the purchase of future goods or services, free goods or services, extended payment terms, or extensions of loyalty programs. Further, because the entity itself may be experiencing financial difficulties and supply disruptions, it may (1) request up-front payments from its customers; (2) delay the delivery of goods or services; (3) pay penalties or refunds for failing to perform, not meeting service-level agreements, or terminating agreements; or (4) incur unexpected costs to fulfill its performance obligations. Therefore, as a result of the changes in circumstances experienced by both an entity and its customers due to the COVID-19 pandemic, an entity may need to consider the following when assessing revenue from contracts with customers:

- **Contract enforceability** — ASC 606-10-25-1 provides criteria that need to be met to account for a contract with a customer, including the approval of the parties to the contract and a commitment to perform their respective obligations. If the criteria are not met, no revenue can be recognized until one of the following occurs: (1) the criteria are met; (2) no obligations to transfer goods or services remain and substantially all of the consideration promised by the customer has been received and is nonrefundable; (3) the contract has been terminated and the consideration received is nonrefundable; or (4) the entity receives nonrefundable consideration, has provided the goods or services related to such consideration, has stopped providing goods or services, and has no obligation to transfer additional goods or services. In certain circumstances, the parties may not be able to approve a contract under an entity's normal and customary business practices. For example, the entity may not be able to obtain the signatures it normally obtains when entering into a contract because personnel from the entity or customer are unavailable or otherwise unable to provide signatures. Therefore, it is important to carefully evaluate whether the approval process creates a contract with enforceable rights and obligations between the entity and its customer. In making this determination, an entity may consider consulting with its legal counsel. If enforceable rights and obligations do not exist, revenue cannot be recognized until certain conditions are met (see above paragraph).

- **Collectibility** — A contract with a customer under ASC 606-10-25-1 does not exist unless “[i]t is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the [promised] goods or services that will be transferred.” That consideration should not include expected price concessions (including implied concessions), which are evaluated as variable consideration, even if those concessions are provided as a result of credit risk. In addition, while the collectibility analysis is performed at the individual contract level, an entity may look to a portfolio of similar contracts (e.g., by risk profile, size of customer, industry, geography) in its assessment. For example, if it is probable that an entity will collect
substantially all the consideration for 90 percent of a portfolio of similar contracts, the entity may conclude that it has met the collectibility threshold for all the contracts in the portfolio. However, an entity should not ignore evidence related to specific contracts that do not meet the collectibility criterion. In that circumstance, it should evaluate those specific contracts separately.

An entity should not reassess whether a contract meets the criteria in ASC 606-10-25-1 after contract inception unless there has been a significant change in facts and circumstances. If the impacts of the COVID-19 pandemic result in a significant deterioration of a customer’s or a portfolio of customers’ ability to pay, the entity should reassess collectibility. For example, if a customer experiences liquidity issues or a downgrade in its credit rating, the entity would need to carefully evaluate whether those circumstances are short-term in nature or result in a determination that it is no longer probable that the customer has the ability to pay. Because of the significant uncertainty associated with the effects of the pandemic, it is important for the entity to document the judgments it made and the data or factors it considered. If the entity concludes that collectibility is not probable, a customer contract no longer exists and, thus, the entity can no longer recognize revenue. If collectibility becomes probable in a subsequent period and the other criteria in ASC 606-10-25-1 are met, the entity can begin to recognize revenue again. See the discussion on contract enforceability above for conditions that need to be met to recognize revenue when an enforceable contract does not exist.

- **Contract modification** — An entity may modify its enforceable rights or obligations under a contract with a customer. For example, the entity may grant a price concession to a customer. In that circumstance, the entity should consider whether the concession is due to the resolution of variability that existed at contract inception (i.e., a change in transaction price associated with variable consideration) or a modification that changes the parties’ rights and obligations. A price concession that is provided solely as a result of the COVID-19 pandemic most likely represents a modification that changes the parties’ rights and obligations. In addition, an entity may modify the scope of a contract (e.g., by reducing minimum purchase commitments). If the modification adds goods or services to the contract, the entity should first evaluate whether the modification is accounted for as a separate contract under ASC 606-10-25-12. However, if the only change to a contract is a reduction of the transaction price, or if the modification is not otherwise a separate contract, the entity should evaluate the guidance in ASC 606-10-25-13 to determine whether the modification should be accounted for as (1) a termination of the old contract and the creation of a new contract because the remaining goods or services are distinct (which results in prospective treatment), (2) a cumulative catch-up adjustment to the original contract because the remaining goods or services are not distinct, or (3) a combination of (1) and (2). If all performance obligations have been satisfied, any price concession would be treated as a change in transaction price under ASC 606-10-32-42 through 32-45.

- **Variable consideration** — Variable consideration includes, among other things, rebates, discounts, refunds (including for product returns), and price concessions. Under ASC 606-10-32-11, an entity should only include amounts of variable consideration in the transaction price if it is not probable that doing so would result in a significant reversal of cumulative revenue recognized when the uncertainty related to the variable consideration is resolved. Further, an entity must update its estimated transaction price in each reporting period. The entity may need to consider any expected changes in (1) its ability to perform and (2) customer behavior as a result of deteriorating economic conditions. For example, an entity may need to consider updating its estimated transaction price if it expects an increase in product returns, decreased usage of its goods or services or decreased royalties, or to potentially pay contractual penalties associated with its inability to perform (e.g., the inability to deliver goods or services on a timely basis or to meet service-level agreements). If there is a reduction
in the estimated transaction price, a change in estimate may result in the reversal of revenue for amounts previously recognized as variable consideration (e.g., as a result of an increase in return reserves). Because of the significant uncertainty associated with the pandemic’s effects on an entity and its customers, it may be challenging for the entity to make appropriate estimates of variable consideration. Therefore, in a manner similar to its assessment of contract collectibility, an entity must document the judgments it made and the data or factors it considered.

Further, an entity may have a right to receive noncash consideration (e.g., shares of stock) from a customer that has declined in value. Because noncash consideration is measured at its estimated fair value at contract inception, any changes in the fair value of noncash consideration after contract inception that are solely due to a decrease in value are not variable consideration and would not be reflected in the transaction price under ASC 606-10-32-23. Rather, the noncash consideration should be accounted for under other GAAP.

- **Material right** — To mitigate any decline in sales, an entity may offer its customers sales incentives, including discounts on future goods or services. In this circumstance, the entity should evaluate whether a sales incentive on the purchase of future goods or services represents (1) a material right under ASC 606-10-55-42 that is associated with a current revenue contract (whether explicit or implicit because there is a reasonable expectation on the part of a customer that he or she will receive a sales incentive at contract inception) or (2) a discount that is recognized in the future upon redemption (i.e., when revenue is recognized for the related goods or services) in a manner consistent with ASC 606-10-32-27.

In addition, for new contracts, an entity may need to update its estimate of the stand-alone selling price of a material right (e.g., because the entity extended the periods for use or provided additional incentives to a customer) or to reassess its breakage assumptions (e.g., because of extensions or changes in expected usage patterns). For example, an entity may modify its loyalty program by extending customers’ ability to use points; this change may require the entity to reassess the breakage assumptions it uses.

- **Significant financing component** — To assist customers that are experiencing liquidity issues in purchasing goods and services, an entity may provide extended payment terms. Similarly, an entity with liquidity issues may require its customers to make an up-front payment in order for the entity to fulfill its promised goods or services. In those circumstances, an entity should evaluate whether a significant financing component exists under ASC 606-10-32-15 through 32-20. If an entity modifies payments terms for an existing customer contract, it should consider the same guidance on price concessions discussed above.

- **Implied performance obligations** — An entity may assist its customers by providing them with free goods or services that are not explicitly promised in the contract. In a manner consistent with ASC 606-10-25-16, an entity should determine whether its contracts with customers contain promised goods or services that are implied by its customary business practices or published policies or by specific statements that create a reasonable expectation of the customer that the entity will transfer those goods or services.

There may also be instances in which an entity provides free goods or services to its customer that are not part of a prior contract with that customer (i.e., when the prior contract was entered into, there were no explicit or implicit obligations to provide those goods or services). An entity must carefully evaluate whether the additional promised goods or services are a modification of a preexisting customer contract or a cost incurred (e.g., marketing expense) that is separate from any preexisting contracts. We believe that in these situations, it may be helpful to consider the
contract combination guidance in ASC 606-10-25-9, which specifies that contracts with the same customer (or related party of the customer) are combined if (1) they “are negotiated as a package with a single commercial objective,” (2) “consideration to be paid in one contract depends on the price or performance of the other contract,” or (3) there are goods or services in one contract that would be a single performance obligation when combined with the goods or services in another contract. In addition, an entity should consider the substance of the arrangement to provide the free goods or services and whether accounting for the arrangement as a separate transaction or as a contract modification would faithfully depict the recognition of revenue related to the goods or services promised to the customer in a preexisting contract. In many cases, free goods or services provided to a customer solely as a result of the COVID-19 pandemic (that are not part of another newly entered contract with that customer) will not be considered a contract modification. However, an entity may need to determine whether it has developed a practice that creates an implied promise in future contracts.

- **Recognition of revenue** — Because of potential supply disruptions or other circumstances, an entity may need to reconsider the timing of revenue recognition if it is unable to satisfy its performance obligations on a timely basis. In addition, the entity must determine whether there are any contractual penalties that would affect the transaction price. In some cases, an entity may be completely unable to satisfy its performance obligation, which could result in (1) the termination of the contract, (2) a reversal of any revenue it previously recognized for a performance obligation that was not fully satisfied, and (3) the recognition of a refund liability (or additional liability due to a payment of penalties) instead of deferred revenue.

An entity may also incur unexpected costs in fulfilling a performance obligation that is satisfied over time. If that entity uses a cost-based input method to measure its progress toward complete satisfaction of the performance obligation, it should carefully consider whether the incremental costs (1) affect its measure of progress or (2) do not depict the entity's performance in transferring control of the goods or services (e.g., because the costs are due to unexpected amounts of wasted materials, labor, or other resources). Therefore, an entity may need to reevaluate the expected costs to complete its contracts and consider future material, labor, and the allocation of overhead rates. Further, an entity that has construction-type and production-type contracts within the scope of ASC 605-35 may also need to consider whether a change in its estimated costs would result in a contract loss that would need to be recognized immediately.

- **Disclosure requirements** — Many of the circumstances described above could affect an entity's disclosures. These include (but are not limited to) disclosures of significant changes in the contract asset due to an impairment, significant payment terms (including any significant financing component), and the timing of when an entity expects to recognize revenue for its remaining performance obligations (which would exclude terminated contracts or transactions that do not meet the criteria in ASC 606-10-25-1 to be accounted for as a customer contract). Given the level of uncertainty caused by the COVID-19 pandemic, an entity may find it challenging to make certain critical estimates. Therefore, it is important for the entity to disclose any significant judgments it made in accounting for its revenue contracts (e.g., assessing collectibility; estimating and constraining variable consideration; measuring obligations for returns, refunds, and other similar obligations; measuring progress toward completion of a performance obligation recognized over time; and determining the stand-alone selling prices and breakage assumptions for material rights).
For health care providers, the CARES Act introduced legislation that could affect the amount of future reimbursements from third-party payors (e.g., Medicare and Medicaid). In addition, it is possible for health care providers to receive advance payments from Medicare for services yet to be rendered. These provisions could require affected entities to reevaluate their estimates of variable consideration and potentially record advance payments received under the CARES Act as a liability. For more information, see Deloitte’s April 9, 2020, *Heads Up*. [Paragraph added April 13, 2020]

**Exit or Disposal Cost Obligations**

As a result of the impacts of COVID-19, entities may incur costs associated with exit or disposal activities (e.g., involuntary employee termination benefits in accordance with a one-time benefit arrangement or costs to consolidate or close facilities and relocate employees). ASC 420 provides guidance on determining when to recognize such costs and the accompanying information that must be disclosed in the notes to financial statements that include (1) the period in which an exit or disposal activity is initiated and (2) any subsequent periods until the activity is completed. See the Employee Termination Benefits section for further discussion of the accounting for involuntary termination benefits associated with ongoing employee benefit plans.

**Loss Contingencies**

ASC 450 defines a loss contingency as “[a]n existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an entity that will ultimately be resolved when one or more future events occur or fail to occur.” Instability in the economy resulting from COVID-19 may cause entities to incur losses that should be recognized, disclosed, or both.

All loss contingencies (including incurred but not reported [IBNR] claims such as those related to medical care) should be evaluated under ASC 450-20 unless the contingency is within the scope of other authoritative literature that specifically prescribes an alternate accounting model. ASC 450-20 requires accrual of a loss contingency when (1) it is probable that a loss has been incurred and (2) the amount can be reasonably estimated. To accrue a loss contingency, an entity must determine the probability of the uncertain event and demonstrate its ability to reasonably estimate the loss associated with it. Loss contingencies that do not meet both recognition criteria may need to be disclosed in the financial statements. Given the general uncertainty associated with the COVID-19 pandemic, entities may find it challenging to develop estimates for loss contingencies. For example, an entity that is self-insured for medical claims may have difficulty estimating its IBNR liability if it concludes that historical claim patterns may not be representative of future expected claims because of the COVID-19 pandemic.

Under ASC 450-20-50, entities must disclose both recognized and unrecognized contingencies, if certain criteria are met. In some situations, disclosure of the nature of the accrual and amount accrued may be necessary to prevent the financial statements from being misleading. For unrecognized contingencies, disclosure of the nature of the contingency and an estimate of the possible loss or range of loss (or a statement that an estimate cannot be made) is required in certain situations. Specifically, disclosure is called for if there is a reasonable possibility that a loss may be incurred but has not been accrued in the financial statements because the amount is not probable or reasonably estimable. Disclosure is also required if there is a reasonable possibility of unrecorded losses in excess of the amount accrued in the financial statements.
Recognition of Losses on Firmly Committed Executory Contracts

At the inception of a firmly committed executory contract, both parties to the contract expect to receive benefits that are equal to or greater than the costs to be incurred under the contract. Because of the impacts of COVID-19, the fair value of the remaining contractual rights of a firmly committed executory contract may unexpectedly decline below the remaining costs, resulting in a firmly committed executory loss contract. For example, an entity engaged to provide services to its customer in accordance with a firmly committed executory contract may experience a significant increase in the cost of providing the services (e.g., lack of availability of personnel to provide services resulting in the use of higher outsourced labor cost), which could result in an overall loss on the contract. We generally believe that in the absence of specific guidance to the contrary (e.g., a firm purchase commitment for goods or inventory under ASC 330 or certain executory contracts subject to ASC 420 related to exit or disposal activities), it is inappropriate to accrue for a loss related to a firmly committed executory contract.

Future Operating Losses

An entity may forecast operating losses for a certain period as a result of the COVID-19 pandemic. Such losses may result from declines in customer demand or disruptions in the supply chain. Future operating losses do not meet the definition of a liability nor do they qualify for accrual under ASC 450-20. Instead, they should be reflected in the period in which the related costs are incurred.

Contractual Penalties

Disruption to operations as a result of the COVID-19 pandemic may contribute to an entity's breach of contractual arrangements, such as revenue and supply contracts, and potentially trigger penalties owed to the counterparty (e.g., a liquidated damage provision). The obligation to pay a penalty in such a scenario does not represent a contingent loss under ASC 450-20 but rather should be accounted for as a contractual liability. The probability of payment is irrelevant if settlement of the liability is required by law or by contract. That is, other than deferred revenues, liabilities established by law or contract should be recorded at their stated amounts unless the guidance in U.S. GAAP requires otherwise. If an entity is required by current laws, regulations, or contracts to make a future payment associated with an event that has already occurred, that event imposes a present duty upon the entity. An entity's uncertainty about whether an obligee will require performance does not (1) allow the entity to choose to avoid the future sacrifice or (2) relieve the entity of the obligation. Once recognized, a contractual or legal liability that is not deferred revenue (i.e., a contract liability under ASC 606) should be derecognized only once the conditions for liability derecognition in ASC 405-20-40-1 have been met (i.e., relief through repayment, or through a legal release either judicially or by the creditor).

Insurance Recoveries

Entities that incur losses stemming from the COVID-19 pandemic may be entitled to insurance recoveries. For example, losses associated with increased medical claims, asset impairments, or shareholder litigation may be considered insured losses by many entities. Furthermore, entities may have business interruption insurance that provides coverage for lost profits due to a suspension of its operations.

Insured Losses

If an entity incurs a loss attributable to the impairment of an asset or to the incurrence of a liability and it expects to recover all or a portion of that loss through an insurance claim, the entity should record an asset for the amount for which recovery from the insurance claim is considered probable (not to exceed the amount of the total losses recognized). The entity should subsequently recognize amounts greater than those for which recovery from
an insurance claim was initially deemed probable only to the extent that those amounts do not exceed actual additional covered losses or direct, incremental costs incurred to obtain the insurance recovery. A conclusion that a potential insurance recovery is probable may involve significant judgment and should be based on all relevant facts and circumstances. In determining whether it is probable that an insurance recovery will be received, an entity will most likely need, among other factors, to understand the solvency of the insurance carrier and have had enough dialogue and historical experience with the insurer related to the type of claim in question to assess the likelihood of payment. Other potential challenges an entity may encounter when evaluating whether a loss is considered recoverable through insurance include, but are not limited to, (1) the need to consider whether losses stemming from a pandemic are specifically excluded as a covered event, (2) the extent of coverage and limits, including multiple layers of insurance from different carriers, and (3) the extent, if any, to which the insurance carrier disputes coverage. Consultation with legal counsel may also be necessary.

**Connecting the Dots**

We believe that while applicable to SEC registrants, the following guidance from footnote 49 of SAB Topic 5.Y applies to all entities evaluating an insured loss that is contested by the insurance carrier:

The staff believes there is a rebuttable presumption that no asset should be recognized for a claim for recovery from a party that is asserting that it is not liable to indemnify the registrant. Registrants that overcome that presumption should disclose the amount of recorded recoveries that are being contested and discuss the reasons for concluding that the amounts are probable of recovery.

Any expected recovery that is greater than covered losses or direct, incremental costs incurred represents a gain contingency and therefore has a higher recognition threshold. An entity should generally recognize insurance proceeds that will result in a gain when the proceeds are realized or realizable, whichever is earlier. Such insurance proceeds are realized when the insurance carrier settles the claim and no longer contests payment. Payment alone does not mean that realization has occurred if such payment is made under protest or is subject to refund.

**Business Interruption**

Recent events associated with the COVID-19 pandemic have led many entities to temporarily suspend operations for reasons ranging from supply chain disruption to, on a broader scale, state and local government orders requiring individuals to shelter in place and temporarily cease operations. Business interruption insurance differs from other types of insurance coverage in that it is designed to protect the prospective earnings or profits of the insured entity. That is, business interruption insurance provides coverage if business operations are suspended because of the loss of use of property and equipment resulting from a covered loss. Business interruption insurance also generally provides for reimbursement of certain costs and losses incurred during the interruption period. Such costs may be analogous to losses from property damage and, accordingly, it may be appropriate to record a receivable for amounts whose recovery is considered probable. We encourage entities to consult with their independent auditors in connection with their evaluation of whether a receivable may be recorded for expected insurance recoveries associated with fixed costs incurred during an interruption period.

The loss of profit margin is considered a gain contingency and should be recognized when the gain contingency is resolved (i.e., the proceeds are realized or realizable). Because of the complex and uncertain nature of the settlement negotiation process, such recognition generally occurs at the time of final settlement or when nonrefundable cash advances are made.

---

**Classification of Insurance Recoveries**

ASC 220-30-45-1 addresses other income statement presentation matters related to business interruption insurance from the perspective of classification and allows an entity to “choose how to classify business interruption insurance recoveries in the statement of operations, as long as that classification is not contrary to existing [U.S. GAAP].”

For presentation within the statement of cash flows, ASC 230-10-45-21B indicates that "[c]ash receipts resulting from the settlement of insurance claims, excluding proceeds received from corporate-owned life insurance policies and bank-owned life insurance policies, shall be classified on the basis of the related insurance coverage (that is, the nature of the loss).” For example, insurance settlement proceeds received as a result of claims related to a business interruption should be classified as operating activities.

**Lease/Rent Concessions**

**[Updated April 13, 2020]**

As a result of the COVID-19 pandemic, certain entities are experiencing significantly reduced consumer traffic in retail stores and shopping areas or indefinite closures as a result of quarantine measures and other government directives. Lessees in some affected markets are receiving rent abatements or other economic incentives and have raised questions about the appropriate accounting. In particular, entities have asked whether such consequences give rise to a lease modification — and thus full application of the modification framework in ASC 840 or ASC 842 — or whether they can be accounted for outside of the modification framework (e.g., as the resolution of a contingency or variable rent expense or income).

Generally speaking, under ASC 840 or ASC 842, economic relief that was agreed to or negotiated outside of the original agreement most likely represents a lease modification, in which case both the lessee and lessor would be required to apply the respective modification frameworks. However, if the lessee was entitled to the economic relief because of either contractual or legal rights, the relief would be accounted for outside of the modification framework.

Without relief related to applying the guidance, an entity would most likely need to perform legal analysis to determine whether contractual provisions in an existing lease agreement provide enforceable rights and obligations related to lease concessions. Given the significant number of leases potentially affected for certain preparers and the volume of contracts that need to be analyzed, this evaluation could become both costly and highly complex for preparers, particularly for smaller companies and those without internal legal counsel. This analysis could be even more complex in jurisdictions in which the local government implements programs that permit or require forbearance.

In the absence of interpretive guidance, the FASB staff acknowledged at the April 8, 2020, Board meeting that determining whether concessions provided to lessees constitute a lease modification under either ASC 842 or ASC 840 would be costly for both lessees and lessors. Accordingly, while the guidance in these standards takes into account lease concessions made in the ordinary course of business, the FASB believes that the guidance did not contemplate wide-ranging and rapidly executed concessions that result from a global pandemic. Further, the staff acknowledged that the economics of these concessions may not be aligned with the underlying premise of the modification framework, under which the concession would be recognized over the remainder of the lease term.

The FASB thus determined that it would be appropriate for entities to make a policy election regarding how to account for lease concessions resulting directly from COVID-19. Rather than analyzing each lease contract individually, entities can elect to account for lease concessions "as though the enforceable rights and obligations for those concessions existed, regardless
of whether those enforceable rights and obligations for the concessions explicitly exist in the contract.”

Accordingly, entities that choose to apply the relief provided by the FASB can either (1) apply the modification framework for these concessions in accordance with ASC 840 or ASC 842 as applicable or (2) account for the concessions as if they were made under the enforceable rights included in the original agreement and are thus outside of the modification framework. Therefore, in making this election, an entity would not need to perform a lease-by-lease analysis to evaluate the enforceable rights and may instead simply treat the change as if the enforceable rights were included or excluded in the original agreement. However, the staff observed that the election not to apply modification accounting is only available when total cash flows resulting from the modified contract are “substantially the same or less” than the cash flows in the original contract. The FASB did not define “substantially the same" but expects companies to apply reasonable judgment in such situations. Further, the Board emphasized that clear and concise disclosure of the accounting policy election remains integral to allow stakeholders to understand the election chosen and the resulting financial reporting implications. Finally, we understand, on the basis of discussions with the SEC staff, that the staff would not object if an entity treats “forgiveness or deferrals” either as a contract modification or as the use of the FASB's election (not a modification). In a manner similar to the FASB, the SEC would limit this option to activity that is both directly related to COVID-19 and does not result in a substantive increase in the remaining contract consideration. The above accounting guidance and optional election are illustrated in the following decision tree.

**Connecting the Dots**

We believe that an entity should make its election either at an entity level (i.e., for all leases) or at another appropriate disaggregated level (e.g., by asset class); however, this issue was not discussed at the meeting. Whatever method a company chooses should be adequately disclosed.

**Consolidation**

The COVID-19 pandemic may give rise to specific transactions or events that could change a reporting entity’s governance rights over other legal entities and thereby affect accounting conclusions for consolidation.

---

8 Quoted text transcribed from the FASB’s meeting.

9 Entities should consult with their accounting advisers regarding the acceptability of the model applied to account for the concession when not applying the modification framework.
The initial assessment of whether a reporting entity is the primary beneficiary of (i.e., has a controlling financial interest in) a variable interest entity (VIE) should be performed on the date on which the reporting entity first becomes involved with a VIE. The reporting entity must then continually reassess whether it is the primary beneficiary of the VIE throughout the entire period the reporting entity is involved with the VIE.\(^\text{10}\) Although continuous assessment of the primary beneficiary is required, because consolidation of a VIE is based on the power to direct the VIE’s activities, it is unlikely that the primary-beneficiary conclusion will change periodically in the absence of specific transactions or events that affect the controlling financial interest in a VIE. Generally, operating losses of a legal entity, in isolation, do not result in a change in the primary-beneficiary conclusion since the VIE model is a consolidation model that is based on power. However, reporting entities should consider whether, as an indirect result of operating losses, there is a change in governance rights that causes a corresponding change in the entity that has the power to direct the activities that most significantly affect the VIE’s economic performance.

An example of how the COVID-19 pandemic could affect whether a reporting entity is the primary beneficiary of a VIE is a default by the legal entity on certain provisions in its debt agreements (e.g., debt covenants or a decline in the fair value of collateral below preapproved levels). Some agreements may contain provisions that, in the event of such a default, give the lender the power to make the decisions that most significantly affect the economic performance of the legal entity. If so, upon default and provided that there are no substantive barriers to the lender’s exercise of such rights, a reporting entity may lose its controlling financial interest in the legal entity. In such instances, other entities involved with the VIE (e.g., a lender) should also reconsider whether they have obtained a controlling financial interest in the legal entity on the basis of specific transactions or events. See Chapter 7 of Deloitte’s *A Roadmap to Consolidation — Identifying a Controlling Financial Interest* for further details.

The events associated with COVID-19 and an economic downturn could also lead to reconsideration of whether a legal entity is a VIE. A reporting entity is required to reconsider whether a legal entity is a VIE upon the occurrence of certain types of events (“reconsideration events”) but should not reconsider whether a legal entity is a VIE on a continual basis or at times other than the specific events outlined in ASC 810-10-35-4. Operating losses incurred by a legal entity that are in excess of its expected losses and result in a reduction of the equity investment at risk generally do not, in isolation, result in the requirement for a reporting entity to reconsider whether the legal entity has sufficient equity investment at risk. However, there may be situations in which significant losses may call into question whether the power to direct the most significant activities of the legal entity still rest with the holders of the equity investment at risk. This may occur, for example, when a legal entity that was controlled by its equity holders subsequently suffers significant losses that result in violation of a covenant that provides the debt holder or a guarantor with a controlling financial interest in the legal entity. This would be deemed a reconsideration event. See Chapter 9 of Deloitte’s *A Roadmap to Consolidation — Identifying a Controlling Financial Interest* for further details.

**Defined Benefit Plans**

The significant economic uncertainty associated with the COVID-19 pandemic will affect the measurement of defined benefit obligations and plan assets, particularly when quoted prices in active markets for identical assets do not exist. Entities may be considering whether a significant decline in the value of plan assets would require interim remeasurement of a defined benefit plan before the normal annual remeasurement. Some insights into navigating the guidance are discussed below.

\(^{10}\) Similarly, the determination of whether a reporting entity should consolidate a voting interest entity (i.e., a legal entity that is not a VIE) is also a continual process. That is, the reporting entity should monitor specific transactions or events that affect whether it holds a controlling financial interest.
Interim Remeasurements

A significant decline in the fair value of plan assets is not an event that requires an interim remeasurement of a defined benefit plan. However, disclosures in the interim financial statements may be required, particularly for entities that may anticipate recognition of significant actuarial losses associated with unrealized losses on plan assets at the end of the year — especially those entities that recognize actuarial gains and losses immediately in the income statement. However, a curtailment, settlement, or material plan amendment of defined benefit plans associated with restructuring activities may trigger the need for an entity to perform an interim remeasurement before the required annual defined benefit remeasurement date. If an interim remeasurement is triggered, the entity should remeasure both the plan assets and the defined benefit obligations.

Plan Assets

An entity’s considerations related to the fair value measurement of financial and nonfinancial assets also apply to the measurement of plan assets under ASC 715. Defined benefit plans may hold significant amounts of assets that do not have an active market, such as investments in hedge funds, structured products, and real estate assets that may become more illiquid, making their valuation more complex. Appropriately determining the fair value of such assets is important in the determination of the funded status of a defined plan (see the Fair Value Measurement and Disclosures discussion for further details).

Defined Benefit Obligations

The discount rate used to value defined benefit obligations under ASC 715 should be set by reference to the yield at which the benefits can effectively be settled. Typically, rates on high-quality bonds (at least AA-rated) that are available currently and expected to be available during the period in which the plan benefits will be paid have been used for this purpose.

In recent years, it has been common for entities to use either a hypothetical portfolio of high-quality corporate bonds, a yield curve based on such bonds, or the average yield on an index of corporate bonds. A volatile economic environment may present challenges to entities’ use of such methods. For example, the spread of yields among the bonds comprising the hypothetical portfolio, yield curve, or published index may indicate that the market no longer considers some of the corporate bonds to be of high quality even though their credit rating has yet to be adjusted. In these circumstances, the portfolio, yield curve, or index should be adjusted to exclude the yields on such bonds. In addition, entities should be able to conclude that the results of using a shortcut to calculate the discount rate, such as an index, are reasonably expected not to be materially different from the results of using a discount rate calculated from a hypothetical portfolio of high-quality bonds.

The approach used by an entity for determining the discount rate should be applied consistently from one period to the next. Further, it may also be appropriate for the entity to consider the reasonableness of the outcome of that approach by comparing it with the outcome of other approaches used to set the discount rate. Finally, depending on the size of the obligation and the sensitivity to changes in the discount rate, an entity should consider disclosing whether its selection of a rate involved a critical judgment or significant accounting estimate.
Stock Compensation Performance Conditions and Service Conditions

Some businesses may cease operations or operate at reduced capacity as a result of the impacts of COVID-19, which could affect the probability that performance targets for share-based payments with performance conditions will be met. ASC 718-10-25-20 requires entities to recognize compensation costs for an equity award with a performance condition in situations in which the outcome of the performance condition is probable. For example, if an award contains a performance condition that affects vesting (such as an award that vests if certain revenue and EBITDA\(^{11}\) growth targets are met) and it is not probable that the performance condition will be satisfied, any previously recognized compensation cost should be reversed. The cessation of an entity’s operations or a reduction in its operating capacity may affect the number of awards that are ultimately forfeited. Entities that have an accounting policy to estimate forfeitures\(^{12}\) associated with service conditions should consider the impact of such business decisions on estimated forfeitures.

In addition, entities may decide to modify the terms or conditions of an equity award. If such modification leads to a change in the fair-value-based measure, vesting conditions, or classification of the award, the modification is treated as an exchange of the original award for a new award. When modification accounting is applied, entities may need to (1) recognize additional compensation cost for any incremental value provided (if the original award was expected to vest on the modification date) or (2) revise the amount of compensation cost by using the modification-date fair-value-based measure (if the original award was not expected to vest on the modification date).

Employee Termination Benefits

Entities may be considering (or implementing) restructuring plans to mitigate their exposures associated with unforeseen consequences of the COVID-19 pandemic. Immediate actions may include measures to reduce their workforce through temporary employee furloughs. Further, entities may be forced to consider subsequent restructuring actions as information becomes available on the long-term effects of the pandemic on an entity’s operations. In addition, in certain jurisdictions, governments may facilitate programs to alleviate some or all of those costs (see the Government Assistance discussion for further detail). There is not a single accounting framework for the accounting for termination benefits; therefore, entities start by identifying the nature and characteristics of each proposed action that is being considered because it may affect the timing of the recognition of the benefits provided to employees:

- **Salary continuation, temporary suspension of employment** — Some entities may offer to continue to compensate employees while not requiring them to provide services over a certain period. Others may implement arrangements to lay off employees on a temporary basis. The guidance in U.S. GAAP does not specifically address these types of arrangements. Therefore, in considering a relevant accounting framework, entities should assess the substance of the benefit offered. That is, if the benefit is more consistent with a compensated absence, it may be appropriate to apply the guidance in ASC 710. Depending on the benefit provided, entities may be required under ASC 710 to recognize the expense (1) when incurred (e.g., on a pay-as-you-go basis) if the benefit does not vest or accumulate or (2) at the time agreed upon with employees if the benefit is already vested. Alternatively, if the benefit is more consistent with one of the forms of termination benefits described below, it may be appropriate to apply that guidance in determining the timing of the recognition of the benefits offered.

---

\(^{11}\) Earnings before interest, tax, depreciation, and amortization.

\(^{12}\) An entity is required to make an entity-wide policy election for both employee awards and nonemployee awards to either (1) estimate forfeitures or (2) recognize forfeitures when they occur.
• **One-time involuntary termination benefits** — ASC 715-30-60-3 states that “one-time termination benefits provided to current employees that are involuntarily terminated under the terms of a one-time benefit arrangement” that, in substance, is not an ongoing benefit arrangement would be accounted for in accordance with ASC 420. In general, the obligation associated with the one-time termination benefit should be measured at fair value in accordance with ASC 420-10-30-5 and should be recognized in either of the following ways:
  
  o If the employees do not have to provide services beyond the minimum retention period, the obligation should be recognized as of the “communication date,” as detailed in ASC 420-10-25-8.
  
  o If, to receive termination benefits, the employees are required to render service until they are terminated and will be retained to render service beyond the minimum retention period, the liability should be recognized ratably over the future service period (e.g., communication date to date of termination).

  Further, ASC 420-10-20 defines the communication date as “[t]he date the plan of termination . . . meets all of the criteria in paragraph 420-10-25-4 and has been communicated to employees.”

• **Involuntary termination benefits as part of an ongoing plan** — If termination benefits to be paid to terminated employees are part of a substantive preexisting ongoing employee benefit plan (e.g., legal minimum indemnities benefits in certain countries or established severance policies), ASC 420 is not applicable. Rather, such benefits should be accounted for in accordance with other guidance, such as ASC 715-30, ASC 715-60, ASC 712, or ASC 710, that generally requires recognition of a liability when it is probable that employees will be entitled to benefits and the amount can be reasonably estimated. That is, it is possible that the conditions to accrue the obligation may be met before the communication date if ASC 420 were to apply.

• **Voluntary termination benefits** — Entities offering a voluntary termination benefit to employees in an effort to reduce their workforce should consider the guidance in ASC 712-10-25-1, which generally requires a liability and loss to be recognized “when the employees accept the offer and the amount can be reasonably estimated.”

Because the accounting for termination benefits discussed above differs on the basis of the type of benefits provided, an entity considering providing enhanced benefits to individual employees over and above the benefits of an ongoing employee benefit plan would find itself having to apply both (1) the guidance on involuntary termination benefits of an ongoing plan and (2) ASC 420 to the enhanced benefits.

**Risks and Uncertainties**

Entities that apply accrual accounting must make estimates in current-period financial statements on the basis of current events and transactions, the effects of which may not be precisely determinable until some future period. The final results may not match original expectations. Uncertainty about the outcome of future events is inherent in economics, and that fact should be understood when reading reports on economic activities, such as published financial statements. A business, to a great extent, is a function of the environment in which it operates. Thus, it can be affected by changing social, political, and economic factors. Further, any entity (or the industry it operates in) may be affected by uncertainties associated with future events. Such uncertainties may or may not be considered contingencies as defined by ASC 450-10-20; accordingly, the disclosures required by ASC 275-10-50 supplement and, in many cases, overlap those required by ASC 450-20-50. For example, some entities may be required to disclose certain significant estimates and their current vulnerability because of concentrations associated with the COVID-19 pandemic.
**Certain Significant Estimates**

ASC 275 states, in part, “Estimates inherent in the current financial reporting process inevitably involve assumptions about future events. . . . Making reliable estimates for those matters is often difficult even in periods of economic stability; it is more so in periods of economic volatility.” Furthermore, ASC 275 requires entities to disclose certain estimates that are susceptible to change (e.g., estimates underlying impairment assessments) if the information known and available to the entity before the financial statements are issued (or available to be issued) meet both of the following conditions:

- It is reasonably possible that the estimate will change in the near term.
- The effect of the change will be material.

Disclosing this information is intended to give financial statement users an early warning that certain estimates inherent in the financial reporting process may materially change in the near term (i.e., within one year from the date of the financial statements). Entities should consider the uncertainty introduced by the impacts of COVID-19 when evaluating whether additional disclosures of certain estimates are required in the financial statements.

**Current Vulnerability Due to Certain Concentrations**

Entities with certain concentrations are exposed to greater risk of loss relative to other entities. Examples of concentrations include those associated with:

- The volume of business with a particular customer, supplier, or lender.
- Revenue from particular products or services.
- The sources of supply of materials, labor, or services.
- The market or geographic area in which an entity conducts its business.

ASC 275-10-50-16 requires disclosure of concentrations if all the following conditions are met:

- “The concentration exists at the date of the financial statements.”
- “The concentration makes the entity vulnerable to the risk of a near-term severe impact.”
- “It is at least reasonably possible that the events that could cause the severe impact will occur in the near term.”

Entities will need to consider whether to provide concentration disclosures as a result of the impacts of COVID-19, particularly if they have met the second condition above.

**Long-Term Intra-Entity Foreign Investments**

ASC 830-20-35-3(b) provides an exception that allows gains and losses on certain intra-entity foreign currency transactions “of a long-term-investment nature” to be treated like translation adjustments instead of being recognized in net income. For a transaction to qualify as a long-term investment, the entity must be able to assert that “settlement is not planned or anticipated in the foreseeable future.” An entity that has characterized intra-entity transactions as part of its net investment in the entity may need to reassess whether that designation is still appropriate in the current economic environment. For example, an entity that plans to undergo restructuring because of the COVID-19 pandemic may need to reassess whether certain intercompany loans that had previously been determined to be of a “long-term-investment nature” should continue to be accounted for as such if the loans could now be settled in the “foreseeable future” in connection with the restructuring plan.
In response to the COVID-19 pandemic, domestic and international governments are considering, or may have implemented, legislation to help entities that have experienced financial difficulty associated with it. One such example is the CARES Act, which provides assistance in the form of loans, grants, tax credits, or other forms of government aid. Although some forms of assistance may be referred to as “grants” or “credits,” entities should carefully look at the form and substance of the assistance to determine the appropriate accounting framework to apply. For example, assistance may be in the form of income-based tax credits that are dependent on taxable income or other forms of government assistance that is not dependent on taxable income (e.g., payroll tax credits). Income-based tax credits generally will be within the scope of ASC 740 (see the Income Taxes discussion for further details). Government assistance that is not dependent on taxable income is generally not within the scope of ASC 740 and would most likely be viewed and accounted for as a government grant.

Exchange Transaction Versus Contribution

The nature and form of government assistance may vary (e.g., grants, payroll tax credits, forgivable loans, price adjustments, reimbursements of lost revenues, reimbursements of expenses). In performing its accounting analysis, an entity should first consider whether the government assistance it receives represents an exchange transaction (i.e., a reciprocal transfer in which each party receives and pays commensurate value) or a contribution, which is defined in the ASC master glossary as an “unconditional transfer of cash or other assets to an entity or a settlement or cancellation of its liabilities in a voluntary nonreciprocal transfer by another entity acting other than as an owner.” To determine whether the government assistance represents an exchange transaction, an entity should consider the factors in the table below, which is adapted from ASC 958-605-15-5A and 15-6 (as amended by ASU 2018-08).

<table>
<thead>
<tr>
<th>An Exchange Transaction May Not Exist if:</th>
<th>An Exchange Transaction May Exist if:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) The benefit provided by the entity is received by the general public, (2) the government only received indirect value from the entity, or (3) the value received by the government is incidental to the potential public benefit derived from using the goods or services transferred from the entity.</td>
<td>The transfer of assets from a government entity is part of an existing exchange transaction between the receiving entity and an identified customer (e.g., payments under Medicare and Medicaid programs). In this circumstance, “an entity shall apply the applicable guidance (for example, Topic 606 on revenue from contracts with customers) to the underlying transaction with the customer, and the payments from the [government] would be payments on behalf of” the customer, rather than payments for benefits that were received by the general public.</td>
</tr>
<tr>
<td>The entity has provided a benefit that is related to “[e]xecution of the [government’s] mission or the positive sentiment from acting as a donor.”</td>
<td>The expressed intent was to exchange government funds for goods or services that are of commensurate value.</td>
</tr>
<tr>
<td>The entity solicited funds from the government “without the intent of exchanging goods or services of commensurate value” and the government had “full discretion in determining the amount of” assistance provided.</td>
<td>Both the entity and the government negotiated and agreed on the amount of government assistance to be transferred in exchange for goods and services that are of commensurate value.</td>
</tr>
<tr>
<td>Any penalties the entity must pay for failing “to comply with the terms of the [government assistance] are limited to the [goods] or services already provided and the return of the unspent amount.”</td>
<td>The entity contractually incurs economic penalties for failing to perform beyond the government assistance provided.</td>
</tr>
</tbody>
</table>
If an entity concludes that the government assistance it received represents an exchange transaction, it should account for such assistance in accordance with the applicable U.S. GAAP (e.g., ASC 606). As discussed further below, certain payments may be considered part of an exchange transaction between the recipient entity and its customers. Furthermore, if a not-for-profit entity concludes that the government assistance represents a contribution, such assistance would be accounted for pursuant to ASC 958-605.

**Connecting the Dots**

Government assistance could include complex provisions; therefore, an entity should carefully apply judgment and consider consulting with its advisers when determining the appropriate accounting treatment. For example, an entity may conclude that assistance is (1) entirely an exchange transaction or (2) partially an exchange transaction and partially a grant. Further, some provisions may only provide for a right to defer payments (for which interest is not imputed in accordance with ASC 835-30-15-3(e)), while others may solely represent a grant from the government (e.g., reimbursement of incurred costs).

**Government Grants**

If the government assistance an entity receives is not accounted for under ASC 740 (e.g., an income-tax-based credit), an exchange transaction (e.g., loan, equity transaction, or revenue arrangement), or a contribution within the scope of ASC 958, it would most likely be viewed as a government contribution of assets and accounted for as a government grant.

Not-for-profit entities should apply ASC 958-605 to the government grants they receive. However, government grants to business entities are explicitly excluded from the scope of ASC 958. Other than the guidance in ASC 905-605-25-1 for income replacement and subsidy programs for certain entities in the agricultural industry, there is no explicit guidance in U.S. GAAP on the accounting for government grants to business entities.

In the absence of explicit guidance in U.S. GAAP for business entities, ASC 105 provides a hierarchy for entities to use in determining the relevant accounting framework for the types of transactions that are not directly addressed in sources of authoritative U.S. GAAP. According to ASC 105-10-05-2, an entity should “first consider [U.S. GAAP] for similar transactions” before considering “nonauthoritative guidance from other sources,” such as IFRS Standards. We have historically maintained that, in applying the hierarchy discussed above, an entity should exclude guidance that either (1) prohibits the entity from applying such guidance to government grants (i.e., see ASC 958-605-15-6(d) for government grants to business entities) or (2) specifies that the guidance should not be applied by analogy. As discussed further below, we understand that there may be diversity in practice.

When selecting the appropriate accounting model to apply to a government grant, a business entity should consider the specific facts and circumstances of the grant. If the entity has a preexisting accounting policy for accounting for similar government grants, it should generally apply that policy. However, if the entity does not have a preexisting accounting policy or the grant is not similar to grants it has received in the past, it should carefully consider applying a model that would faithfully depict the nature and substance of the government grant.

We believe that in the absence of either directly applicable or analogous U.S. GAAP, it may be appropriate to apply IAS 20, which has been widely used in practice by business entities to account for government grants.

---

13 See ASC 958-605-15-6(d).
14 For titles of IFRS Standards, see the list on the IFRS Web site.
Connecting the Dots
While we believe that IAS 20 has been widely applied in practice by business entities in accounting for government grants, the application of ASC 450-30 may also be acceptable since we are aware that some business entities may have applied a gain contingency model by analogy for certain grants (e.g., the Electronic Healthcare Records program under the American Recovery and Reinvestment Act of 2009). Under this model, income from a conditional grant is viewed as akin to a gain contingency; therefore, recognition of the grant in the income statement is deferred until all uncertainties are resolved and the income is “realized” or “realizable.” That is, an entity must meet all the conditions required for receiving the grant before recognizing income. For example, a grant that is provided on the condition that an entity cannot repurchase its own shares before a certain date may result in the deferral of income recognition until the compliance date lapses. Such a deferral may be required even if (1) the government funded the grant, (2) the entity incurred the costs that the funds were intended to defray, and (3) the remaining terms subject to compliance are within the entity's control and virtually certain of being met. That is, it would not be appropriate under a gain contingency model for an entity to consider the probability of complying with the requirements of the government grant when considering when to recognize income from the grant. Therefore, for many grants, the recognition of income under ASC 450-30 would most likely be later than the recognition of income under IAS 20.

In addition, we understand that some believe that it may be acceptable in practice to apply other U.S. GAAP for government grants. For example, while government grants to business entities are explicitly excluded from the scope of ASC 958, some may believe its application is still acceptable by analogy, particularly if the grant received by a business entity is similar to that received by a not-for-profit entity (e.g., certain subsidies provided to both nonprofit and for-profit health care providers). Further, some may believe that loans obtained should be accounted for as debt in their entirety under ASC 470, even if all or a portion of the loan is expected to be forgiven. Under ASC 405-20, income would not be recorded from the extinguishment of the loan until the entity is legally released from being the primary obligor.

We expect to have further discussions with standard setters or regulators regarding which accounting models may be appropriate or acceptable. Preparers should monitor any future developments in this area.

IAS 20 Accounting Framework
An entity that elects an IAS 20 framework to account for government grants should consider that such grant cannot be recognized (even if payment is received up front) until there is reasonable assurance that the entity will (1) comply with the conditions associated with the grant and (2) receive the grant. While “reasonable assurance” is not defined in IAS 20, for a business entity that is subject to U.S. GAAP, we believe that reasonable assurance is generally the same threshold as “probable” as defined in ASC 450-20 (i.e., “likely to occur”).

When an entity has met the reasonable assurance threshold, it applies IAS 20 by recognizing the government grant in its income statement on a “systematic basis over the periods in which the entity recognises as expenses the related costs for which the grants are intended to compensate.” To help an entity meet this objective, IAS 20 provides guidance on two broad classes of government grants: (1) grants related to long-lived assets (capital grants) and (2) grants related to income (income grants).
Capital Grants
A capital grant is a grant received by an entity with conditions tied to the acquisition or construction of long-lived assets. An entity may elect an accounting policy to initially recognize such a grant as either deferred income or a reduction in the asset’s carrying amount. If the entity classifies the grant as deferred income, it will recognize the grant in the income statement over the useful life of the depreciable asset that it is associated with (e.g., as an offset against depreciation expense). If the entity classifies the grant as a reduction in the asset’s carrying amount, the associated asset will have a lower carrying value and a lower amount of depreciation over time. Further, with respect to nondepreciable assets, IAS 20 observes that “[g]rants related to non-depreciable assets may also require the fulfilment of certain obligations and would then be recognised in profit or loss over the periods that bear the cost of meeting the obligations. As an example, a grant of land may be conditional upon the erection of a building on the site and it may be appropriate to recognise the grant in profit or loss over the life of the building.”

Income Grants
An income grant is a grant that is not related to long-lived assets. An entity may present the receipt of such a grant in the income statement either as (1) a credit to income (in or outside of operating income) or (2) a reduction in the related expense that the grant is intended to defray. As discussed above, the main objective of the accounting for government grants under IAS 20 is for an entity to recognize a grant in the same period or periods in which it recognizes the corresponding costs in the income statement. Therefore, an entity should assess the specific compliance requirements that it must meet to receive or retain any funds from the government.

**Connecting the Dots**
Income-related government grants that are intended to compensate for expenses incurred over time may also include over time compliance requirements. Applying IAS 20 could therefore allow for over time recognition of the grant if the entity can assert that it is likely to comply with the conditions (i.e., the grant is reasonably assured).

However, if an entity instead applied the ASC 450-30 gain contingency framework to these types of grants, recognition of the government grant would generally be delayed until all conditions were met because the probability of compliance is not taken into consideration in the application of ASC 450-30.

While IAS 20 identifies two broad classes of grants, it is worth noting that some grants may include multiple requirements and have aspects of both capital grants and income grants. That is, such grants may be intended to subsidize the purchase of long-lived assets and certain operating costs. Therefore, an entity receiving a grant that is subject to multiple requirements should carefully assess how to allocate such a grant into components on a systematic and rational basis to accomplish the overall objective of matching recognition of the grant to recognition of the cost in the income statement.

**Statement of Cash Flows**
When an entity receives a capital grant, the timing of the cash payment it receives from the government for long-lived assets could affect the cash flow classification. If the entity receives the cash after it has incurred the capital costs, it would be appropriate to present the cash inflow from the government in the same category (i.e., investing) as the original payment for those long-lived assets. However, if the government provides the funds before the expenditures have been incurred, it would be appropriate for the entity to present that cash inflow as a financing activity because receiving the cash before incurring the related cost would be similar to receiving a refundable loan advance. In addition, when the entity
incurs the costs in accordance with the conditions of the government grant, it should disclose the existence of a noncash financing activity resulting from the fulfillment of the grant requirements.

Similarly, if an entity receives an income grant as reimbursement for qualifying operating expenses, the grant would be presented in the statement of cash flows as an operating activity if it was received after the operating expenses were incurred. However, some entities may believe that in cases in which cash is received before the qualifying operating expenses are incurred, it would be appropriate to present the cash inflow as a financing activity for the advance (e.g., forgivable loans) in a manner consistent with the guidance above. Alternatively, others may believe that it is acceptable to present the cash inflow as an operating activity if the entity expects to comply with the terms of the grant (e.g., an advance on future payroll taxes credit) so that both the inflow and outflow are presented in the operating category.

Disclosures

Although there currently is no authoritative guidance in U.S. GAAP on disclosure requirements for government grants received by business entities, the FASB initiated a project in 2015 to address disclosures that entities should provide for government assistance they receive. In 2015, the Board issued a proposed ASU that described several disclosures that it considered relevant and useful to stakeholders. Such disclosures included a general description of the significant categories of government assistance and disclosures of (1) the form in which the assistance has been or will be received, (2) the financial statement line items that are affected (noting that such assistance may be presented as a separate line in the statement of operations), (3) significant terms and conditions of the government assistance, and (4) any government assistance received but not recognized directly in the financial statements. While the project continues to be listed on the FASB’s active agenda, there is no scheduled date for further redeliberations. In the absence of authoritative guidance, we believe that it is critical for an entity to disclose its accounting policy for government grants if the amounts are material to its financial statements.

See Deloitte’s April 9, 2020, Heads Up for further information and financial reporting considerations related to government assistance associated with the CARES Act.

Income Statement Classification Considerations

Entities may need to determine whether the financial effects (i.e., incremental operating gains or losses) stemming from the COVID-19 pandemic should be reported or disclosed in the financial statements as a separate component of income from continuing operations.

Under ASC 220-20-45-1, if an entity concludes that a material event is of an unusual nature or occurs infrequently (or both), the entity must either report the nature and financial effects of the event as a separate component of income from continuing operations or provide disclosure in the notes to the financial statements. Under this guidance, “unusual nature” represents a situation in which the underlying event has a high degree of abnormality and not related to the ordinary activities of the entity. Furthermore, “infrequency of occurrence” represents an event that would not reasonably be expected to recur in the foreseeable future. We believe that most companies will consider COVID-19 to be unusual or infrequent and that a decision about whether to separately disclose related amounts would therefore primarily be based on the materiality of the impact on its financial statements.

The determination of the amounts to be either separately reported or disclosed may involve a significant degree of judgment because ASC 220-20 does not provide measurement guidance for determining the financial effects of a qualifying event. While the authoritative guidance is not clear, we believe that a reasonable interpretation of how to determine the financial effects

would most likely include direct and incremental costs or benefits related to the COVID-19 pandemic (e.g., asset impairments, cleaning costs, business interruption insurance recoveries).

Income statement presentation for public companies is also addressed in SEC Regulation S-X, Rule 5-03,\(^{16}\) for commercial and industrial companies. In certain instances, the SEC has given registrants flexibility in disaggregating the components of required line items on the face of the statement of comprehensive income. Registrants that are significantly affected by the COVID-19 pandemic may consider presenting a separate line item or line items on their statement of comprehensive income to show the impact of this unusual or infrequent event. To the extent that an entity elects to present a separate line item or line items on its statement of comprehensive income, we encourage it to transparently disclose both the nature and amount of all costs included in the line item(s) in the footnotes to the financial statements and in MD&A.

Registrants that present a separate line item or line items for the impact of COVID-19 should consider the effect on gross profit or operating income subtotals presented. For example, while Rule 5-03 does not require a subtotal for gross profit, certain costs such as inventory impairment are expected to be part of costs of sales (and therefore included in gross profit) by analogy to ASC 420-10-599-3. In addition, under Rule 5-03, a subtotal for operating income is not required on the face of the income statement; but if a registrant presents a subtotal for operating income, it should generally present any COVID-19 related line item as part of operating income.\(^ {17}\) Further, we believe that a separately presented COVID-related line item should not be preceded by a subtotal such as “income before COVID-related amounts” (whether or not it is so captioned).

**Going Concern**

COVID-19 is significantly disrupting the operations of many businesses. Entities will need to consider whether such disruption will be prolonged and result in diminished demand for products or services or significant liquidity shortfalls (or both) that, among other things, raise substantial doubt about whether the entity may be able to continue as a going concern.

As part of performing this assessment, management may need to consider whether the entity's financial statements should continue to be prepared on a going-concern basis (i.e., whether ASC 205-30 is applicable). Even more importantly, management must consider whether (on the basis of ASC 205-40), (1) there are conditions and events that, when considered in the aggregate, raise substantial doubt about the entity's ability to continue as a going concern within one year after the date on which the interim or annual financial statements are issued and (2) these conditions are able to be mitigated by management's plans.

ASC 205-40 requires an entity to provide disclosures in the annual and interim financial statements when events and conditions are identified that raise substantial doubt about the entity's ability to continue as a going concern within one year after the financial statements are issued. Such disclosures are required even when management's plans alleviate such doubt about the entity's ability to continue as a going concern. If management's plans do not alleviate substantial doubt about the entity's ability to continue as a going concern, in addition to the required disclosures, management must state in the notes to the financial statements that there is substantial doubt about the entity's ability to continue as a going concern within one year after the date on which the annual or interim financial statements are issued.

---

\(^{16}\) For titles of and links to SEC Regulation S-X rules, see the e-CFR Web site.

\(^{17}\) However, to the extent that an entity concludes that a nonoperating gain or loss is COVID-related, we would expect the gain or loss to remain a nonoperating item (i.e., the classification as “COVID-related” does not change the characteristic of the gain or loss as operating versus nonoperating).
As indicated in ASC 205-40-55-2, assessing whether there is substantial doubt about an entity’s ability to continue as a going concern may involve the consideration of factors such as the following:

a. Negative financial trends, for example, recurring operating losses, working capital deficiencies, negative cash flows from operating activities, and other adverse key financial ratios. [Some of these items, such as working capital deficiencies and short-term negative cash flows from operating activities, may directly apply to an entity affected by COVID-19.]

b. Other indications of possible financial difficulties, for example, default on loans or similar agreements, arrearages in dividends, denial of usual trade credit from suppliers, a need to restructure debt to avoid default, noncompliance with statutory capital requirements, and a need to seek new sources or methods of financing or to dispose of substantial assets. [These items may or may not apply to an affected entity.]

c. Internal matters, for example, work stoppages or other labor difficulties, substantial dependence on the success of a particular project, uneconomic long-term commitments, and a need to significantly revise operations. [Among these items, project dependence and long-term commitments would perhaps be the most applicable to an affected entity.]

d. External matters, for example, legal proceedings, legislation, or similar matters that might jeopardize the entity’s ability to operate; loss of a key franchise, license, or patent; loss of a principal customer or supplier; and an uninsured or underinsured catastrophe such as a hurricane, tornado, earthquake, or flood. [These circumstances are probably the most relevant to affected entities but also the most unpredictable given the unprecedented nature of the pandemic.]

**Subsequent Events**

Given the economic environment and the likelihood that events may occur rapidly or unexpectedly, entities should carefully evaluate information that becomes available after the balance sheet date but before the issuance of the financial statements. ASC 855-10-25-1 and ASC 855-10-25-3 provide the following guidance on evaluating subsequent events:

An entity shall recognize in the financial statements the effects of all subsequent events that provide additional evidence about conditions that existed at the date of the balance sheet, including the estimates inherent in the process of preparing financial statements. See paragraph 855-10-55-1 for examples of recognized subsequent events.

An entity shall not recognize subsequent events that provide evidence about conditions that did not exist at the date of the balance sheet but arose after the balance sheet date but before financial statements are issued or are available to be issued. See paragraph 855-10-55-2 for examples of nonrecognized subsequent events.

Often the “events” are (1) company specific and (2) associated with a specific account that permits a more precise analysis. However, sometimes the “events” are macroeconomic in nature (such as those resulting from COVID-19) and have a pervasive impact on many estimates in a set of financial statements, which may make it difficult to ascertain whether such conditions “existed” on the balance sheet date. The full impact of the COVID-19 pandemic on short-term, medium-term, and long-term economic activity is still unknown, and major developments are occurring frequently. However, COVID-19 will be a factor in an entity’s analysis of estimates residing in the financial statements, including, but not limited to, estimates related to receivable reserves, obsolescence reserves, impairment analyses, variable and contingent compensation, and CECL reserves. While the events stemming from COVID-19 are extremely volatile, entities will nevertheless be required to consider conditions as they existed on the balance sheet date when evaluating subsequent events. There are currently many approaches to the consideration of subsequent events in complex estimate analyses such as impairment models (e.g., whether changes in circumstances that alter projection models before issuance date can be considered given the fluidity of the situation).

While there are no bright lines regarding the establishment of a particular date in the evaluation of subsequent events stemming from the COVID-19 pandemic, we would expect that for entities with a balance sheet date in February 2020 or before, much of what is known about events related to COVID-19 for operations in the United States would most likely be
viewed as unrecognized subsequent events rather than recognized subsequent events. For example, many of the orders by state and local governments (e.g., shelter in place or business closings) and the related negative impacts on the economy would not be indicative of a condition that existed at the end of February 2020 or before because such actions were both announced and went into effect at various points after February 2020. Furthermore, and while not conclusive in and of itself, the declaration by the WHO on March 11, 2020, of COVID-19 as a pandemic is seen by many as a significant data point that informed the subsequent decisions by national, state, and local governments.

To the extent that the financial reporting effects stemming from the COVID-19 pandemic are accounted for as a nonrecognized subsequent event, entities should consider disclosure when material. ASC 855-10-50-2 notes that “[s]ome nonrecognized subsequent events may be of such a nature that they must be disclosed to keep the financial statements from being misleading.” In such circumstances, the disclosures must include (1) the “nature of the event” and (2) an “estimate of its financial effect, or a statement that such an estimate cannot be made.”

Given the fluid state of affairs with respect to the COVID-19 pandemic and the significant judgment that will most likely need to be applied in assessments related to subsequent event matters, entities are encouraged to consult with their advisers as needed.

Entities should also consider the potential for subsequent-event accounting and reporting associated with the CARES Act’s March 27, 2020, enactment. For more information, see Deloitte’s April 9, 2020, Heads Up. [Paragraph added on April 13, 2020]

**Income Taxes**

Entities should consider how profitability, liquidity, and impairment concerns that could result from the impacts of COVID-19 might also affect their income tax accounting under ASC 740. For example, a reduction in current-period income or the actual incurrence of losses, coupled with a reduction in forecasted income or a forecast of future losses, could result in (1) a reassessment of whether it is more likely than not that some or all of an entity’s deferred tax assets are realizable and (2) a need to recognize a valuation allowance. Such assessments will be particularly challenging in situations in which the changes in current and projected future profitability actually result in or are expected to result in cumulative losses in recent years and the entity has not had a stable earnings history before the impacts of COVID-19. If declining earnings or impairments generate losses, entities also need to consider the character (i.e., capital or operating) of such losses and evaluate whether there is sufficient income of the appropriate character to fully realize the related deferred tax asset.

Adjustments to forecasted income (like those assumed for other impairment analyses) will also need to be factored into an entity’s estimated annual effective tax rate (AETR). In some cases, the reduction in forecasted income might be accompanied by a similar reduction in tax (e.g., if the entity has only insignificant permanent items or permanent items that increase or decrease proportionately to ordinary income), resulting in only small changes to the AETR. If, however, an entity’s permanent items are more significant and do not “scale,” the entity’s AETR might be highly sensitive to changes in estimated ordinary income for the year, rendering any individual AETR estimate unreliable. In those instances, the actual effective tax rate for the year to date may be the best estimate of the AETR.

Similarly, if an entity or its subsidiaries have liquidity issues, or other issues resulting from the current economic environment, an entity may also need to reassess whether undistributed earnings of foreign subsidiaries are still indefinitely reinvested or whether a deferred tax liability should now be recorded for an outside basis taxable temporary difference in a foreign subsidiary. While most entities have already recorded U.S. tax on a significant portion of their
undistributed foreign earnings and profits, repatriation of such undistributed earnings and profits may still trigger currency gains and losses and be subject to additional withholding or to state or other income taxes.

Entities should account for changes in tax law (including those related to the CARES Act) in the period that includes the enactment date of such changes. Entities should also be aware that not all forms of tax relief and tax credits will fall within the scope of ASC 740; those that can only be monetized against non-income-based taxes (e.g., payroll taxes) would be accounted for in accordance with other literature. [Paragraph updated April 13, 2020]

**Internal Control Considerations**

Because of the impact of COVID-19, entities may need to implement new internal controls or modify existing ones. Entities must disclose in their quarterly or annual filings any changes in internal controls that have materially affected, or are reasonably likely to materially affect, their internal control over financial reporting (ICFR) in Item 4 of Form 10-Q or in Item 9A of Form 10-K (or in Item 15 of Form 20-F for foreign private issuers).

Entities will need to consider the operating effectiveness of controls, including assessing any breakdown in review-type controls or the inability of individuals to perform control duties because of absences (e.g., because of employee illness or the closure of affected locations). Entities should also consider how a lack of information may affect management’s ability to effectively operate controls (e.g., personnel may not be available in affected areas to provide information that is essential to the effective operation of an internal control). If an existing control cannot be performed, management may need to identify alternative appropriately designed controls to compensate for the lack of information as well as to potentially identify and evaluate control deficiencies.

Entities should also consider management’s ability to complete its financial reporting process and prepare its financial statements on a timely basis. Delays in closing the underlying financial records may increase the potential for error in the financial statements and merit the use of new or modified controls to offset the increased risk of potential financial statement error. In addition, entities will need to ensure that they have properly designed and implemented controls related to the selection and application of GAAP for the accounting and disclosure issues arising from the COVID-19 pandemic. See additional COVID-related ICFR considerations on Deloitte Accounting Research Tool (DART).

**Financial Reporting Under ASC 852 for Entities in Reorganization Under the Bankruptcy Code**

If an entity files for bankruptcy under Chapter 11 of the Bankruptcy Code after the balance sheet date but before issuance of the financial statements, the reporting requirements under ASC 852 do not apply. However, the filing itself and pertinent items related to the Chapter 11 filing should be disclosed as required by ASC 855-10-50-2 (see the Subsequent Events discussion for further detail).

**Operating During a Chapter 11 Reorganization**

The following are some key considerations for entities operating under a Chapter 11 reorganization:

- **Consolidation** — If a subsidiary of a reporting entity files for bankruptcy in the United States under Chapter 11, or seeks similar relief in a foreign jurisdiction (e.g., the Companies’ Creditor Arrangement Act in Canada), the reporting entity would need to assess the specific facts and circumstances of that event to determine whether deconsolidating the subsidiary would be appropriate (e.g., deconsolidation may result

---

18 For example, as a result of the deemed repatriation transition tax in the Tax Cuts and Jobs Act of 2017.
if the reporting entity does not retain power over the subsidiary’s most significant activities during bankruptcy). 19

- **Cessation of the recognition of interest expense** — In accordance with ASC 852-10-45-11, “[i]nterest expense shall be reported only to the extent that it will be paid during the [bankruptcy] proceeding or that it is probable that it will be an allowed priority, secured, or unsecured claim.” The full amount of interest expense based on the contractual rate should be parenthetically disclosed on the face of the income statement or in the footnotes to the extent that the amount is different from that recorded.

- **Classification of current or noncurrent liabilities** — When an entity files for bankruptcy under Chapter 11, all liabilities existing as of the petition date are automatically stayed (cannot be paid) unless payment is approved by the Bankruptcy Court. In accordance with ASC 852-10-45-4 and 45-5, an entity would need to assess such liabilities to determine whether they are expected to be impaired (i.e., creditors are not expected to receive payment in full upon completion of the Chapter 11 proceeding). All such liabilities should be adjusted to their estimated allowed claim amounts and reclassified to a new financial statement line item entitled “liabilities subject to compromise.” The new classification would not be considered current or long-term and typically would be presented below noncurrent liabilities.

- **Income statement classification considerations** — If an entity files for bankruptcy under Chapter 11, all income, expense, gain, or loss items directly related to the Chapter 11 proceeding should be separately classified as “reorganization items” in accordance with ASC 852-10-45-9.

- **Debtor-only financial statements** — In accordance with ASC 852-10-45-14, “[c]onsolidated financial statements that include one or more entities in reorganization proceedings and one or more entities not in reorganization proceedings shall include condensed combined financial statements of the entities in reorganization proceedings. The combined financial statements shall be prepared on the same basis as the consolidated financial statements.”

## Emerging From a Chapter 11 Reorganization

Entities emerging from Chapter 11 must apply the assessment in ASC 852-10-45-19 to determine whether they are required to adopt fresh-start reporting. Key accounting implications for an entity that has adopted fresh-start reporting include:

- **Balance sheet impacts** — In accordance with ASC 805, the reorganization value of the entity must be allocated to the entity’s assets and liabilities. ASC 852-10-45-20 states that “[i]f any portion of the reorganization value cannot be attributed to specific tangible or identified intangible assets of the emerging entity, such amounts shall be reported as goodwill in accordance with paragraph 350-20-25-2.” In addition, because the implementation of fresh-start reporting results in a new reporting entity, historical equity accounts such as accumulated other comprehensive income and retained earnings are adjusted to an opening balance of zero.

- **Four-column footnote** — The entity’s footnotes will contain a four-column presentation of the balance sheet as of the effective date of the entity’s plan of reorganization, including the historical-basis balance sheet immediately before the effective date of such plan, adjustments to reflect the impacts of the plan, and adjustments to allocate the entity’s reorganization value to its identified tangible and intangible assets and

---

19 Reporting entities that apply the equity method to account for investments in common stock or in-substance common stock on the basis of having the ability to exercise significant influence over operating and financial policies of the investee may need to assess the specific facts and circumstances of a bankruptcy by an equity method investee to determine whether they continue to meet the criteria to apply the equity method (e.g., continue to have significant influence over an investee during bankruptcy).
liabilities in accordance with ASC 805, resulting in the opening balance sheet of the successor entity.

- **Income statement impacts** — As required by ASC 852-10-45-21, forgiveness of debt, if any, is reported as an extinguishment of debt and classified as a reorganization item. In addition, the effects of the adjustments on the reported amounts of individual assets and liabilities from the adoption of fresh-start reporting must be reflected as a reorganization item. Both the effects of the forgiveness of debt and the remeasurement of assets and liabilities must be reflected in the final income statement of the predecessor entity (the reporting entity ending on the effective date).

- **Segregation of predecessor and successor periods** — As a result of the implementation of fresh-start reporting, the balance sheet and statement of operations of the successor are not comparable to those of the predecessor entity. Accordingly, when comparative periods are presented, a black-line presentation should be used to divide the balance sheet, the statement of operations, and cash flow information between the predecessor and successor periods. Implementation of fresh-start reporting during a fiscal year will result in short-period statements of operations and cash flows for the predecessor and successor. Such a black-line presentation should also be applied to all footnote disclosures of balance sheet, income statement, and cash flow information.
Appendix A — Industry-Specific Insights

Background
Appendix A expands on the content in the body of this Alert by providing industry-specific consideration points. It should not be viewed in isolation; rather, it should be read in conjunction with the body of this Alert.

The appendix discusses key accounting and financial reporting considerations related to the impact of the COVID-19 pandemic on the following industries:

- Banking and Finance
- Media and Entertainment
- Real Estate
- Oil and Gas
- Power, Utilities, and Renewables
- Aerospace and Defense
- Life Sciences
- Consumer
  - Transportation
    - Airlines
    - Shipping and Logistics
    - Passenger Ground Transportation
  - Hospitality and Services
    - Hotels, Resorts, and Casinos
    - Restaurants and Food Services
    - Cruise Lines
  - Retail
  - Automotive
Banking and Finance Industry

Many entities in the banking and finance industry are directly affected by the COVID-19 pandemic, which has already jolted financial markets. Since February 21, 2020, bond yields, oil, and equity prices have decreased sharply across almost all asset classes. In the United States, 10-year bond yields have fallen, as have equity prices on major stock indexes around the world. While such a downturn could have a significant adverse impact on banking and finance companies, current and future announcements of government programs that support banks and their customers will also affect financial results.

While not all-inclusive, the discussion below summarizes some of the more significant financial and reporting considerations for entities within the industry.

Financial Instruments — Impairment and Valuation Considerations

Banking and finance entities are significantly affected by an economic downturn because of the nature of their business activities — such as providing credit through consumer and commercial loans, investing in equity and debt securities, writing guarantees, and entering into derivatives. See the Financial Instruments and Contract Assets discussion for a full description of financial reporting considerations related to the accounting for financial instruments.

Regardless of whether an entity still assesses loans for impairment under the incurred model of ASC 320 or uses the CECL model in ASC 326, an economic downturn will have a significant impact on the allowance for credit losses. However, the economic uncertainty will have more profound effects on companies that are adopting CECL in 2020. The effective date of CECL depends on the nature of the reporting entity.20

Once adopted, the new guidance will significantly change the accounting for credit impairment. Although not all-inclusive, the discussion below highlights specific considerations related to CECL.

Estimation of Allowance

Because of the forward-looking nature of ASC 326, macroeconomic forecasting is a significant aspect of estimating expected credit losses. The assumptions used in making such estimates include, but are not limited to, trends in the gross domestic product (GDP), consumer price index, regional or national unemployment rates, and regional or national home price indexes. Once such trends are identified, an entity can develop appropriate forecasts from internal or external sources, or both. During times of economic uncertainty, an entity must identify and evaluate the macroeconomic assumptions it uses in the estimate. Such an evaluation should include consideration of whether the entity’s processes, data, and assumptions are responsive to current economic conditions, which may not be the same as those that existed on the date it transitioned to CECL. Examples in which the judgments an entity applied during transition to CECL (e.g., as of January 1, 2020) may need to change on a future date (e.g., March 31, 2020) include the entity’s evaluation of the following (see Section 4.3 of Deloitte’s A Roadmap to Accounting for Current Expected Credit Losses for further discussion of the information set used in a CECL estimate):

- A reasonable and supportable forecast period.
- Segmentation of the portfolio, including an increase in loans that no longer have common credit characteristics.
- The relevant historical loss period to use after reversion.
- New qualitative factors stemming from new or existing limitations in data, models, and assumptions.
- The determination of the industries that are most affected — retail, oil and gas, and hospitality.
- Model performance in adverse economic scenarios that may not have been fully tested.
- Lags or delays in credit risk ratings, which may be exacerbated by the fact that employees are working remotely.
- The impact of running models on a lag basis and whether the lag period is appropriate.

20 For SEC filers that do not meet the definition of a smaller reporting company (SRC), CECL is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all others, CECL is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, is permitted. See Section 9.1.1 of Deloitte’s A Roadmap to Accounting for Current Expected Credit Losses for the definition of an SEC filer and SRC. Section 4014 of the CARES Act also provides an optional deferral for certain qualifying entities (see Deloitte’s April 9, 2020, Heads Up for further information). [Footnote updated April 13, 2020]
In addition, an economic downturn can have a significant impact on loan-level factors and estimates, including the expected value of the collateral underlying the lending arrangement. For example, a bank with significant exposure to nonrecourse lending arrangements to the energy sector may have large loan losses because of declines in the fair value of the collateral underlying the lending.

Internal Control
The controls that an entity uses to determine the allowance for credit loss are likely to include management review controls designed to operate in combination with controls over the information that supports the inputs (including the assumptions) upon which the estimate is based. As discussed above, the economic downturn could result in changes in data, models, and assumptions, all of which affect internal controls. For example, an entity may need to implement controls over the relevance and reliability of data from new sources or to validate changes in its models. With employees working remotely, an entity should consider internal controls over how information is shared and how robust discussions occur in management review controls, including the governance over setting the allowance for credit losses. Certain underwriting and credit risk monitoring control activities, such as inventory observations and appraisals for collateralized borrowings, are generally done on site; thus, they could be disrupted by COVID-19 precautions.

Transition Adjustment
As discussed above, calendar-year public business entities that are SEC filers, except for SRCs, adopted CECL on January 1, 2020. Some have questioned whether any of the estimated impacts of COVID-19 that are calculated during the first quarter of 2020 could be “pushed back” into the transition adjustment as of January 1, 2020. Although COVID-19 was identified as of January 1, 2020, we generally do not believe that the recent events (e.g., failure of containment, subsequent spread, declaration of a global pandemic, and the severe impact on global economics) were known or knowable as of the CECL transition date. Therefore, it would not be appropriate to use hindsight in determining the CECL transition adjustment. Rather, the impact on the CECL estimate, if any, related to the more recent COVID-19 developments after the transition date should be considered in the first quarter of adoption, with any change in the estimate from COVID-19 affecting the income statement.

Loan Commitments
Off-balance-sheet arrangements, such as commitments to extend credit, guarantees, and standby letters of credit, are subject to credit risk; therefore, arrangements that are not considered derivatives under ASC 815 are within the scope of the CECL model. Accordingly, under ASC 326, an entity’s method for determining the estimate of expected credit losses on the funded portion of a loan commitment must be similar to its method for determining the estimate for other loans. For an unfunded portion of a loan commitment, an entity must estimate expected credit losses over the full contractual period over which it is exposed to credit risk under an unconditional present legal obligation to extend credit. Such an estimate takes into account both the likelihood that funding will occur and the expected credit losses on commitments to be funded.

Many commercial banks have large portfolios of off-balance-sheet lending commitments, which are in the scope of the CECL standard. Historically, funding of loans under these lending facilities may have been low for certain industries or portfolios because of strong macroeconomic performance and the borrowers’ lack of liquidity needs. Banks generally use these historical funding levels to develop their expectations of future funding. Therefore, banking and finance entities will need to carefully evaluate their assumptions about funding given the likelihood that recent events will cause borrowers to have greater needs for liquidity. See Chapter 5 of Deloitte’s A Roadmap to Accounting for Current Expected Credit Losses for further information on accounting for loan commitments under CECL.
**Subsequent Events**

Economic uncertainty may continue to evolve for the foreseeable future. When estimating an allowance for credit loss related to on- and off-balance-sheet exposures, banking and finance entities must consider the impact of subsequent events that occur after the end of a reporting period. For example, certain macroeconomic factors (e.g., unemployment) will not be available on March 31, 2020; instead, the data will typically be reported in April. In a December 10, 2018, speech, the SEC staff addressed the consideration of subsequent events in various scenarios and generally indicated that it would not object to the inclusion (or omission) of information that extends beyond the balance sheet date as long as it is not loan-specific (e.g., unemployment or other macroeconomic factors). However, if the information is loan-specific and is about factual conditions that existed as of the balance sheet date (e.g., a loan servicer or appraisal report), the entity must consider the information as of the balance sheet date even if it was received after the end of the reporting period. See Section 4.8 of Deloitte’s *A Roadmap to Accounting for Current Expected Credit Losses* for further information.

**Goodwill**

The economic downturn has unique and challenging implications for banking and finance entities, including financial exposure to (1) consumer borrowers who may become unemployed or underemployed as a result of any governmental measures to curb the spread of the virus and (2) borrowers in industries that are affected by the downturn. In addition, a tightening of credit markets and a decrease in interest rates may compress projected profitability. Given the sudden decrease in the market value of many public banks in the first quarter of 2020 and the uncertain economic forecast, entities may need to test goodwill for impairment. For further discussion, see the Goodwill section.

**Troubled Debt Restructurings**

[Updated April 13, 2020]

Banking and finance companies often modify the payment terms of a loan when the borrower is experiencing financial difficulties and will be unable to make payments under the contract. ASC 310-40 establishes the accounting and reporting requirements for a TDR, which occurs when (1) the debtor is experiencing financial difficulties and (2) the creditor grants a concession to the terms of the lending arrangement. A concession can take many forms, which range from extending payment terms to reducing required payments. However, a restructuring that results in only an insignificant delay in payment is not considered a concession for purposes of determining whether a TDR has occurred. In accordance with ASC 310-40-15-17, an entity should consider the following factors together when evaluating whether a delay in payment is insignificant:

a. The amount of the restructured payments subject to the delay is insignificant relative to the unpaid principal or collateral value of the debt and will result in an insignificant shortfall in the contractual amount due.

b. The delay in timing of the restructured payment period is insignificant relative to any one of the following:
   1. The frequency of payments due under the debt
   2. The debt's original contractual maturity
   3. The debt's original expected duration.

For an entity that has not yet adopted ASC 326, a loan restructured in a TDR is an impaired loan. To calculate the impairment, the entity would perform a discounted cash flow analysis of the loan by using the effective interest rate of the loan before the modification as the discount rate. This analysis essentially requires the lender to recognize a loss for the adverse change in cash flows resulting from the modification (in both amount and timing).

For an entity that has adopted ASC 326, the allowance for credit losses should factor in the effects of a TDR when a TDR is reasonably expected at the individual loan level. In addition, the contractual life of a loan should take into account any extensions resulting from the reasonably expected TDR.

Regardless of whether ASC 326 has been adopted, an entity must comply with ongoing disclosure requirements related to a loan restructured through a TDR over the remaining life of the restructured loan.
Banking and finance companies may modify the terms of loans because of the impact of the pandemic on the borrowers' financial resources. In fact, banking and finance companies may roll out large-scale relief programs, potentially even in response to mandates from governmental authorities. Some of these programs may even be offered to borrowers that are current on their payments.

On March 22, 2020, the Federal Deposit Insurance Corporation, the Board of Governors of the Federal Reserve System, the Office of the Comptroller of the Currency, the National Credit Union Administration, the Conference of State Bank Supervisors, and the Consumer Financial Protection Bureau issued the Interagency Statement on Loan Modifications and Reporting for Financial Institutions Working With Customers Affected by the Coronavirus (the “Interagency Statement”) to encourage financial institutions to work constructively with borrowers affected by COVID-19 and provide additional information regarding loan modifications. The Interagency Statement states that the “agencies have confirmed with [the FASB staff] that short-term modifications made on a good faith basis in response to COVID-19 to borrowers who were current prior to any relief, are not TDRs. This includes short-term (e.g., six months) modifications such as payment deferrals, fee waivers, extensions of repayment terms, or other delays in payment that are insignificant. Borrowers considered current are those that are less than 30 days past due on their contractual payments at the time a modification program is implemented” (footnote omitted).

In addition, the Interagency Statement states that “[m]odification or deferral programs mandated by the federal or a state government related to COVID-19 would not be in the scope of ASC 310-40, e.g., a state program that requires all institutions within that state to suspend mortgage payments for a specified period.”

On March 22, 2020, the FASB also issued a statement, in which the Board acknowledged the Interagency Statement and confirmed that the “guidance [in the Interagency Statement] was developed in consultation with the staff of the FASB who concur with this approach and stand ready to assist stakeholders with any questions they may have during this time.”

Section 4013 of the CARES Act provides temporary relief from the accounting and reporting requirements for TDRs associated with certain loan modifications related to COVID-19 that are offered by “financial institutions.”

Specifically, a financial institution may elect to suspend (1) the requirements under U.S. GAAP for certain loan modifications that would otherwise be categorized as a TDR and (2) any determination that such loan modifications would be considered a TDR, including the related impairment for accounting purposes. The modifications that would qualify for this exception include any modification involving a loan that was not more than 30 days past due as of December 31, 2019, and that occurs during the “applicable period,”22 including any of the following:

- A forbearance arrangement.
- An interest rate modification.
- A repayment plan.
- Any other similar arrangement that defers or delays the payment of principal or interest.

The relief does not apply to any adverse impact on the credit of a borrower that is not related to the COVID-19 pandemic.

The CARES Act and the interagency statement overlap in many areas, but they are not consistent. For example, the interagency statement requires an entity to evaluate whether the borrower is less than 30 days past due at the time a modification program is implemented, while under the CARES Act, that determination is made as of December 31, 2019. In addition, the CARES Act allows interest rate modifications to occur on the loans, whereas the interagency statement only provides relief for modifications associated with the timing of payments (e.g., deferrals).

---

21 A financial institution is not a defined term in the CARES Act or GAAP. Entities may need to discuss with their legal counsel whether they are within the scope of Section 4013 of the CARES Act.

22 The applicable period for loan modifications means the period beginning on March 1, 2020, and ending on the earlier of (1) December 30, 2020, or (2) the date that is 60 days after the termination date of the national emergency declared by President Trump under the National Emergency Act on March 13, 2020, related to the outbreak of COVID-19.
On April 3, 2020, SEC Chief Accountant Sagar Teotia issued a statement regarding actions the SEC has been taking in response to COVID-19. He indicated that for those financial institutions that are eligible to apply the provision of the CARES Act related to the modification of loans, an election to apply that provision would be in accordance with GAAP.

In addition, the SEC staff continues to collaborate with the FASB staff, the AICPA, banking regulators, and other stakeholders on some of the related implementation questions, including the relationship between the CARES Act and the interagency statement. Regarding that relationship, the banking agencies issued on April 7, 2020, a revised interagency statement to clarify the interaction between the March 22, 2020, interagency statement and Section 4013 of the CARES Act. According to the revised interagency statement, financial institutions may account for eligible loan modifications under Section 4013 of the CARES Act, and any loan modification that does not meet the conditions in that section may still qualify as a modification that does not need to be accounted for as a TDR. The agenda for the FASB’s April 8, 2020, meeting notes that the Board “will help its stakeholders interpret guidance related to priority issues, including troubled debt restructurings and lease modifications.” However, the Board did not discuss TDRs at that meeting.

Entities may find the following flowchart (which reflects the above announcements and guidance provided to date) to be helpful as they navigate the scope of modifications as TDRs:

The guidance in the flowchart below only applies during the COVID-19 pandemic and cannot be applied to modification programs unrelated to COVID-19 in the future.
Although the interagency guidance applies to financial institutions regulated by the agencies that issued it, because the guidance was developed in consultation with the FASB staff, which concurred with the approach, we believe that nonfinancial institutions may also elect to apply the guidance.

Under the CARES Act, a modification may include a forbearance arrangement, an interest rate modification, a repayment plan, and any other similar arrangement that defers or delays the payment of principal or interest.

This would apply only if the lender had no option to avoid granting the modification.

We believe that two three-month consecutive delays, for example, could be acceptable.
Entities that apply the TDR guidance discussed in Section 4013 of the CARES Act or the revised interagency statement will need to consider providing relevant disclosures in the notes to the financial statements and, for SEC registrants, in MD&A. On the basis of informal discussions, we understand that the Division of Corporation Finance believes that many of the suggested disclosures on loan modifications that were discussed in a speech made in December 2010 would be relevant disclosures for loan modifications related to COVID-19.

**Interest Income During Payment Holidays**

*Added April 13, 2020*

At the FASB's April 8, 2020, meeting, the FASB staff discussed a technical inquiry regarding the recognition of interest income by an institution that was assisting borrowers affected by COVID-19. The institution provided a “loan payment holiday,” during which borrowers could temporarily stop payments and interest would not legally accrue. The loan modification did not represent a TDR, nor would it be accounted for as an extinguishment of the original loan and the recognition of a new loan.

Two views were expressed related to the technical inquiry:

- **View 1** — “Upon modification, a new effective interest rate in accordance with Subtopic 310-20 is determined that equates the revised remaining cash flows to the carrying amount of the original debt and is applied prospectively for the remaining term. That is, interest income is recognized during the payment holiday period.”
- **View 2** — “Upon modification, the institution should recognize interest income on the loan in accordance with the contractual terms. Under this view, the institution would recognize no interest income during the payment holiday and would resume recognizing interest income when the payment holiday ends."

The FASB staff noted that it believed that both views were acceptable.
Media and Entertainment Industry

Many entities in the media and entertainment industry are directly affected by COVID-19. While not all-inclusive, the discussion below summarizes some of the more significant considerations for entities within the industry.

Live Events

Revenue Recognition

Many sports and entertainment entities have cancelled or postponed live events. These entities will need to consider a number of potential implications, including whether refund provisions exist or whether they need to provide other concessions for previously sold tickets, sponsorships, venue rentals, etc. Such provisions may affect revenue recognition in the period.

In addition, many sports and entertainment entities license the exhibition rights of live events to media broadcasters and similar entities. For example, a regional sports network may have the exhibition rights to broadcast the games of a professional sports team in a certain market. In this case, both the licensor (e.g., the professional sports team) and the licensee (e.g., media broadcaster) would need to carefully consider the payment terms under the license agreement and whether such payments would continue or need to be refunded under a “stoppage of play” scenario. For the licensor, this may affect the timing and amount of revenue recognition under the license agreement. The licensee should consider whether it needs to update the amount and pattern by which it recognizes license payments over the license term. Further, the licensee may have contractual agreements with distribution partners in which it receives consideration in exchange for delivering a certain number of the live sporting events. In such circumstances, entities should apply similar considerations to those related to the stoppage of play scenario.

Media companies will also need to consider any previously sold advertising time during live event broadcasts. Such sales agreements may include audience ratings or impression guarantees that may not be met in the absence of the live event (e.g., if the game or match is not played). In such instances, entities will need to consider (1) the timing and pattern of revenue recognition and (2) whether they need to establish a refund liability.

For further discussion, see the Revenue Contracts With Customers section.

Production Costs

Entities may have previously incurred production costs in connection with an upcoming event. If these costs have been capitalized, entities will need to determine whether such costs are recoverable or should be written off in the period. In addition, entities should carefully consider whether such production costs are subject to insurance coverage and, if so, determine when to recognize the proceeds. For further discussion, see the Insurance Recoveries section.

Film Ultimates and Impairment

Film studios are also experiencing weaker than expected box office performance because of theater closures in response to the pandemic, which may affect the expected ultimate revenues over the life of a film. ASC 926-20-35-3 requires entities to “review and revise estimates of ultimate revenue as of each reporting date to reflect the most current available information.” Accordingly, film studios should carefully consider the impact of recent events and whether they need to revise their estimates of ultimate revenue.

Many studios have also announced delays in the theatrical releases of movies or have currently halted production. Under ASC 926-20-35-12, 35-12A, and 35-12B, entities must test unamortized film costs for impairment whenever events or facts and circumstances suggest that the fair value of a film (film group) may be less than its unamortized cost. While not all inclusive, the following examples listed in ASC 926-20-35-12A are indicators that an impairment test should be performed for a film.

a. An adverse change in the expected performance of a film prior to [its] release
b. Actual costs substantially in excess of budgeted costs

27 For entities that have adopted FASB Accounting Standards Update No. 2019-02, Improvements to Accounting for Costs of Films and License Agreements for Program Materials.
28 See footnote 27.
c. Substantial delays in completion or release schedules

d. Changes in release plans, such as a reduction in the initial release pattern

e. Insufficient funding or resources to complete the film and to market it effectively

f. Actual performance subsequent to release failing to meet expectations set before release due to factors such as the following:
   1. A significant adverse change in technological, regulatory, legal, economic, or social factors that could affect the public's perception of a film or the availability of a film for future showings
   2. A significant decrease in the amount of ultimate revenue expected to be recognized

g. A change in the predominant monetization strategy of a film resulting in the film being predominantly monetized with other films and/or license agreements.

While not all inclusive, the indicators in ASC 926-20-35-12B provide examples of circumstances in which an impairment test should be performed for a film group:

   a. A significant adverse change in technological, regulatory, legal, economic, or social factors that could affect the fair value of the film group
   b. A significant decrease in the number of subscribers or forecasted subscribers, or the loss of a major distributor
   c. A current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection of continuing losses associated with the use or exploitation of a film group.

Accordingly, entities will need to carefully evaluate the impact of recent events to determine whether a film (film group) may be impaired. For instance, they should consider whether a decision to delay the release of a film is solely a result of COVID-19 uncertainty or whether there are other underlying concerns regarding the film's expected performance.
Real Estate Industry
The real estate industry may be affected by the potential impacts of COVID-19, which include an increase in telecommuting, social distancing, temporary business closures, school closures, event cancellations, changes in shopping patterns, and disruptions in talent and workforce models. The effect on each subsector of the real estate industry and on each geographic location may be different. As the events and conditions related to COVID-19 evolve, it will be important for entities in the real estate industry to monitor and evaluate their accounting- and disclosure-related responses.

While not all-inclusive, the discussion below highlights some of the more significant financial and reporting considerations for entities in the real estate industry.

Impairment of Long-Lived Assets, Including Real Estate Assets
Real estate entities should evaluate and consider the impacts of COVID-19, including any tenant-related changes or disruptions, and determine whether there are any new indicators of impairment. See the Long-Lived Assets discussion for further information.

Rent Relief and Other Support for Tenants
As a result of the pandemic, lessors could be asked or have obligations to provide rent rebates or other rent relief (such as a temporary decrease in rent or a change to variable lease payments that depend on sales). In these cases, lessors should consider the FASB’s relief that applies when certain circumstances related to COVID-19 are met (i.e., the cash flows are substantially the same or lower), which permits them to treat the concession as a modification or not a modification without performing an evaluation on a contract-by-contract basis. See the Lease/Rent Concessions discussion for further information.

Disclosure Considerations
Real estate entities should provide disclosures about the impacts of the pandemic consistently throughout all their SEC filings (including Forms 10-K, 10-Q, and 8-K, and registration statements). Similarly, such disclosures should also be provided consistently within a specific filing. For example, the Risk Factors section should cover specific risks related to pandemics and the related impact from actions such as office closures, event cancellations, social distancing, and changes in the workforce model. The Business and MD&A sections should include any effects on operational metrics (such as occupancy changes), liquidity, lease collectibility, and any early-warning disclosures of upcoming impairments, including disclosures of any impairment triggers. Given the pervasive use of joint venture and equity method investment structures in the industry, real estate entities may also need to consider whether they will be able to obtain sufficient information and audited financial statements from their equity method investees to comply with their SEC Regulation S-X requirements (specifically, Rules 3-09, 4-08(g), and 10-01(b)(1)). See the SEC Reporting and Disclosure Considerations discussion for further information, including the use of non-GAAP measures.
Oil and Gas Industry

Early in 2020, oil prices began a steady decline, driven partially by the impacts of the COVID-19 outbreak on the worldwide economy. Oversupply and declining demand have led to the erosion of more than 50 percent of the value of crude oil since December 31, 2019, and the benchmark U.S. oil price has fallen to below $30 a barrel. Oil futures have also declined in a similar fashion. The lower oil prices may reduce the viability of drilling since the cost of extracting the oil or natural gas may exceed the revenue generated (e.g., it may not be profitable to drill in certain areas).

As entities in the upstream sector curtail the number of drilling rigs that they are actively running in their programs, they may seek cost reductions from service providers, including those in the midstream and oil field services sector. This will result in a slowdown in services provided by midstream entities as a result of fewer actively working rigs in 2020 and, therefore, fewer wells to be completed and brought online.

Accordingly, upstream entities will need to consider their particular facts and circumstances, including any potential early-warning signs of negative revisions of proved reserves as well as the related impairment implications, when performing their impairment assessments.

Upstream Impairment Considerations — Successful-Efforts Method

Entities that use the successful-efforts method apply the guidance in ASC 932-360-35 and ASC 360-10-35 to account for the impairment of their oil and gas (O&G) assets. Under the successful-efforts method, a company generally performs a traditional two-step impairment analysis in accordance with ASC 360 whenever an event or change in circumstance indicates that the asset group's carrying amount may not be recoverable.

Upstream Impairment Considerations — Full-Cost Method

Exploration and production companies that use the full-cost method of accounting should apply the guidance in SEC Regulation S-X, Rule 4-10, SAB Topic 12.D, and FRC Section 406.01.c to assess whether O&G assets are impaired.

Under the full-cost method, a full-cost ceiling test must be performed on proved properties in each reporting period. The evaluation is prescribed and is not reflective of fair value. The primary differences between the full-cost ceiling test and an evaluation performed under the successful-efforts method are as follows:

• Commodity pricing is based on the historical 12-month weighted average price rather than on future commodity pricing.
• Companies discount cash flows at 10 percent rather than perform a two-step process under which the discount in step 1 is zero and market-based in step 2.

The full-cost accounting approach requires a write-down of the full-cost asset pool when net unamortized cost less related deferred income taxes exceeds (1) the discounted cash flows from proved properties (i.e., estimated future net revenues less estimated future expenditures to develop and produce proved reserves), (2) the cost of unproved properties not included in the costs being amortized, and (3) the cost of unproved properties included in the costs being amortized. The write-down would be reduced by the income tax effects related to the difference between the book basis and the tax basis of the properties involved.

Midstream and Oil Field Service Company Impairment Considerations

Midstream and oil field service companies will need to consider how a reduction in upstream activity may affect their operations and associated accounting. For example, considerations may include the impairment of long-lived assets under ASC 360, the impairment of goodwill under ASC 350, and liquidity.

30 SEC Codification of Financial Reporting Policies, Section 406.01.c, “Full Cost Method.”
Power, Utilities, and Renewables Industry

The impacts of COVID-19 on the power, utilities, and renewables (PU&R) industry continue to evolve. The magnitude of the effects will most likely depend largely on the level of the supply chain disruption and the economic downturn in affected regions. Entities will need to carefully consider any governmental policy directives in response to the pandemic. In certain markets, governments may attempt to provide financial relief to citizens through measures that could include reducing utility bills; such directives may directly affect local utility providers. The COVID-19 pandemic is expected to affect both regulated and unregulated operations.

Two impacts of the pandemic that could affect financial reporting for entities in the PU&R industry are discussed below.

**Impact of Supply Chain Disruption on Construction Timelines**

Construction timelines in the renewable energy sector are under pressure because of supply chain disruptions in China and elsewhere. Foreign markets produce many of the components used in the solar industry, in particular. Such disruptions could affect both residential applications and large-scale projects. In some cases, these disruptions could jeopardize a developer’s ability to complete construction in time to qualify for federal tax credits. Often, the tax credits are necessary to make the project economically viable, and some developers will have to face difficult decisions about completing construction or abandoning the project. In other cases, development pipelines will be affected by the scarcity of available financing. In the United States, failure to obtain financing and begin construction by the end of 2020 will jeopardize a project’s eligibility for tax credits unless the federal government extends the deadline or offers targeted relief to lessen the impact of COVID-19. Affected entities should consider the financial reporting implications, including asset impairment and impairment of capitalized development costs. There may also be disclosure considerations, including concentration risk with respect to supply chain issues and the risk associated with meeting the tax credit deadlines.

**Impact of Government Policy Initiatives on Customer Billing Practices**

Customer accounts receivable are generally reported net of a provision for uncollectible accounts. Certain segments of a utility customer base may experience employment layoffs or other displacements related to COVID-19, which may negatively affect the customers’ ability to pay utility bills on a timely basis. This could result in a short-term phenomenon of “slow-pays and no-pays” as customers react to the current environment. In addition, some utilities have volunteered to cease all service shutoffs for nonpayments for a specified period, and some entities may ultimately be subject to other types of payment abatement programs imposed by regulators or governments. As a result, it will be important for utilities to carefully consider what credit losses to expect in the current environment. When evaluating the payments it expects to receive from customers, an entity should consider issues associated with a customers’ ability to pay as well as the entity’s payment accommodations. For some utilities, any incremental bad debt expenses that arise from the current circumstances may be recoverable in future rates; in such cases, the entity should consider whether a regulatory asset should be recorded for these costs.
Aerospace and Defense Industry

The impacts of COVID-19 on the aerospace and defense industry are quickly evolving and may be extensive for the commercial portion of the industry. Among the many impacts are restrictions on travel, reduced customer liquidity, and supply chain disruption. The magnitude of the effects on aerospace and defense entities will vary depending on a particular entity's mix of commercial and defense customers, the products the entity manufactures, and the entity's location. Such entities will also need to consider the impacts of any government assistance that may be provided.

Other key considerations for aerospace and defense entities are discussed below.

**Inventory**

Entities may experience changes in production levels because of temporary shutdowns, a reduction in the number of production shifts, or both. Entities will need to use judgment in determining what constitutes abnormal production levels in their circumstances. ASC 330-10-30-4 states that the “range of normal capacity will vary based on business- and industry-specific factors. Judgment is required to determine when a production level is abnormally low (that is, outside the range of expected variation in production).”

**Accounting for Estimates of Contract Costs and Variable Consideration**

An entity may need to reevaluate the expected costs of completing its contracts and consider the estimated impact of the costs of future material, labor costs, and the allocation of overhead rates given the availability of resources and the supply chain. In addition, entities will need to exercise judgment in evaluating whether changes in costs affect the measure of progress. Assumptions used to estimate variable consideration may also need to be updated on the basis of current circumstances. Further, an entity that has construction- and production-type contracts within the scope of ASC 605-35 may also need to consider whether a change in its estimated costs would result in a contract loss that would need to be recognized immediately.

**Contract Assets and Accounts Receivable**

Entities may need to evaluate the recoverability of existing contract assets and accounts receivables on the basis of updates to future cost and revenue estimates for individual contracts, customer behavior, and individual circumstances and modifications.

**Delays in Government Funding**

Contracts may be funded annually or at more frequent intervals. Entities may need to consider whether delays in government contracting may increase the risk of unfunded inventory levels, which may affect revenue recognition.
Life Sciences Industry

Many entities in the life sciences industry are directly affected by COVID-19. The Food and Drug Administration (FDA) has acknowledged potential disruption to the industry as a result of the COVID-19 pandemic. In March 2020, the FDA published guidance on the significant disruption to the conduct of clinical trials, which states, in part:

FDA recognizes that the COVID-19 pandemic may impact the conduct of clinical trials of medical products. Challenges may arise, for example, from quarantines, site closures, travel limitations, interruptions to the supply chain for the investigational product or other considerations if site personnel or trial subjects become infected with COVID-19. These challenges may lead to difficulties in meeting protocol-specified procedures, including administering or using the investigational product or adhering to protocol-mandated visits and laboratory/diagnostic testing. FDA recognizes that protocol modifications may be required, and that there may be unavoidable protocol deviations due to COVID-19 illness and/or COVID-19 control measures.

3 For the purposes of this guidance, the term investigational product refers to human drugs and biological products, and medical devices.

While not all-inclusive, the discussion below summarizes some of the unique considerations for entities in the industry.

**Failure-to-Supply Penalties in Sales Contracts May Increase**

Some contracts with customers include a clause requiring the entity to pay a penalty to the customer if it is unable to fulfill an order on a timely basis or to meet certain performance conditions specified in the contract. Life sciences entities may be more likely to incur penalties as a result of supply chain disruption because of the concentration of active pharmaceutical ingredient (API) manufacturing in China. As illustrated in ASC 606-10-55-194, Example 20, an entity should consider such penalties to be variable consideration in estimating the transaction price with the customer. Furthermore, and as discussed in the **Contractual Penalties** section, the obligation to pay a penalty under such a scenario, once triggered, does not represent a contingent loss under ASC 450-20; rather, the obligation should be accounted for as a contractual liability. The probability of payment is irrelevant if settlement of the liability is required by law or by contract. That is, other than deferred revenues, liabilities established by law or contract should be recorded at their stated amounts unless the guidance in U.S. GAAP requires otherwise. An entity's uncertainty about whether an obligee will require performance does not (1) allow the entity to choose to avoid the future sacrifice or (2) relieve the entity of the obligation. Once recognized, a contractual or legal liability that is not deferred revenue (i.e., a contract liability under ASC 606) should be derecognized only when the conditions for liability derecognition in ASC 405-20-40-1 have been met (i.e., relief through repayment, or through a legal release either judicially or by the creditor).

**Retroactive Payback Provisions May Require Reestimation**

In certain countries, companies are required to pay rebates to the country's government health care system if domestic industry sales exceed specified thresholds in a given year. In such a case, the portion of the payback allocated to an individual company is based on that company's current market share (or sales) in relation to the industry as a whole. For revenue recognition purposes, a retroactive payback provision represents variable consideration that would need to be estimated, subject to the variable consideration constraint. Given the significant health care costs being incurred in many jurisdictions with such provisions, the likelihood that domestic industry sales will exceed specified thresholds may be higher than initially estimated. In addition, a life sciences entity's market share could be negatively affected by supply chain disruption as a result of the COVID-19 pandemic. Therefore, an entity may need to consider revising its estimates of such provisions.

**Delays in FDA Approvals Could Have Accounting Implications for Indefinite-Lived IPR&D Assets and Contingent Consideration Liabilities**

In a March 10, 2020, statement, FDA Commissioner Dr. Stephen Hahn noted:

After careful consideration, the FDA is postponing most foreign inspections through April, effective immediately. Inspections outside the U.S. deemed mission-critical will still be considered on a case-by-case basis. . . . We are aware of how this action may impact other FDA responsibilities, including product application reviews. We will be vigilant and monitor the situation very closely and will try to mitigate potential impacts from this outbreak in lockstep with the whole of the federal government. We stand ready to resume foreign inspections as soon as feasible.
Under ASC 350-30-35-18, an “intangible asset that is not subject to amortization shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.” The delay in product application reviews could represent a qualitative indicator that the value of capitalized in-process research and development (IPR&D) is impaired, thus necessitating an impairment test. Furthermore, additional uncertainty in regulatory approval caused by a delay in product application reviews could affect the estimate of contingent consideration liabilities that have been recorded in connection with either a previous asset acquisition or business combination if such contingent payments are related to regulatory approval and commercialization milestones.

**Potential Impact on Contract Research and Development Arrangements**

Life sciences entities that have contractual arrangements to perform contract research and development (R&D) for others (e.g., biotechs and contract research organizations) may experience a significant increase in the cost of performing contract R&D (e.g., the inability of an entity's personnel to perform monitoring visits or to enroll patients in clinical trials), which could have revenue recognition implications. For example, an entity that uses a cost-based input method to measure its progress toward complete satisfaction of a performance obligation would need to reevaluate whether its measure of progress is affected by a significant increase in the overall cost of the R&D program or whether such increased costs should be excluded from the measure of progress because they do not depict the entity's performance in transferring control of the contract R&D (e.g., if the costs are due to unexpected amounts of wasted materials, labor, or other resources). Furthermore, the potential disruption in an entity's performance of contract R&D could affect its estimate of variable consideration in circumstances in which the entity is entitled to receive R&D milestone payments if (1) clinical trial regulatory approvals are received by a certain date or (2) regulatory approval for commercialization is ultimately achieved, or (3) both.
Consumer Industry

Transportation, Hospitality, and Services

The transportation, hospitality, and services industry has suffered amid the COVID-19 pandemic and faces operating cost, cash flow, and liquidity pressures that are likely to affect 2020 results and future forecasts. Revenues of airlines, cruise lines, and other transportation companies, along with those of hospitality and service companies (including hotels and resorts, casinos, restaurants, and food services companies), are expected to be considerably reduced in 2020.

Transportation Sector

Airlines

Some consider airlines to be at the epicenter of the COVID-19 pandemic. Airlines are facing rapidly changing operating and financial challenges because of governmental and business travel restrictions and declining consumer and business demand for air travel. Several major airlines have indicated a reduction in flight operations and schedules. While increased sanitation expenses may be offset by lower oil prices, which may have a positive impact on airline fuel costs, the potential for significant reduction of flight operations, idling of aircraft, and reduction in airline staffing remains a risk. The major airlines are currently evaluating the adequacy of cash positions, access to liquidity, and prolonged reductions in demand and revenue, all of which could materially affect airline operations.

Noteworthy accounting considerations include:

- Impairment of long-lived assets (e.g., aircraft, goodwill and other intangibles) due to reductions in aircraft utilization, idling of aircraft, and profitability challenges.
- Liquidity, covenant compliance, and going-concern considerations resulting from potentially prolonged declines in revenue and demand.
- Restructuring costs related to potential staff reductions due to reductions in flight demand.
- Evaluation of key assumptions for estimating the customer loyalty program obligations since prolonged reductions in demand can affect such assumptions (e.g., estimated breakage of loyalty points). Changes to customer loyalty programs in light of current conditions, such as an entity's decision to voluntarily extend expiration terms, should be monitored and evaluated; these changes may result in more frequent revisions to breakage assumptions and estimates.
- Evaluation of impacts on revenue recognition related to changes in airline cancellation and change fee policies.

Shipping and Logistics

Shipping and logistics businesses tend to be cyclical and generally are directly affected by product supply and demand. These businesses can also be affected by staff illnesses or absences, which could delay product delivery. As a result of potential workforce shortages and other supply chain issues (e.g., reductions in product availability), shipping and logistics companies may face challenges in managing the timely delivery of products in periods of high demand.

Noteworthy accounting considerations include:

- Liquidity, covenant compliance, and going-concern considerations to the extent that volume and revenue decline as a result of either reduced product demand or a workforce shortage.
- Impairment of long-lived assets, particularly vessels (since entities may need to sell or scrap vessels to maintain liquidity).
- Evaluation of the timing of revenue recognition since product delays, crewing issues, or delays at ports may require reevaluation of the voyage time (which affects revenue recognition).
- Evaluation of accounts receivable for collectibility.
**Passenger Ground Transportation**

Passenger ground transportation businesses, including public and private modes of transportation, are being affected by COVID-19 as governments and businesses are curtailing travel and encouraging employees to work from home. Typically, passenger ground transportation businesses benefit from the volume of deplanements. However, airlines have experienced recent declines and planned reductions, which have translated into lower demand for passenger ground transportation services.

Noteworthy accounting considerations include:

- Liquidity, covenant compliance, and going-concern considerations resulting from potentially prolonged declines in revenue due to reductions in travel, the inability to modify fleet purchase commitments, and the adverse effect of the pandemic on the timing of fleet sales.

- Impairment of long-lived assets, including goodwill and other intangibles. In particular, when considering impairment of long-lived assets, an entity may need to reconsider fleet residual values.

- Evaluation of key assumptions for estimating the customer loyalty program obligations since prolonged reductions in demand can affect such assumptions (e.g., estimated breakage of loyalty points). Changes to customer loyalty programs in light of current conditions, such as an entity’s decision to voluntarily extend expiration terms, should be monitored and evaluated; these changes may result in more frequent revisions to breakage assumptions and estimates.

**Hospitality and Services Sector**

**Hotels, Resorts, and Casinos**

Hotel, resorts, and casino businesses are experiencing the impacts of COVID-19 as room rates, occupancy levels, and overall resort property revenues decline as a result of reduced demand associated with restrictions on travel and social gatherings. Hotels and integrated resorts, including resorts with casino, entertainment, convention, retail, food and beverage, and ancillary revenue operations, are experiencing business challenges in the face of declining consumer demand and both mandatory and voluntary property closures.

Noteworthy accounting and internal control considerations include:

- Evaluation of revenue recognition related to changes in cancellation policies, stand-alone selling prices for complimentary rooms, and management company agreements that include incentive fees and the achievability of those targets.

- The likelihood that entities will experience postponements or full cancellations of individual leisure travel reservations, conventions, and sporting and entertainment events for which advance sales amounts, deposits, and wagers may have been collected. Entities will need to evaluate the appropriate timing of recognition, measurement, and classification of contract liabilities as a result of the impact of COVID-19 on overall global travel. Potential changes to cancellation policies or contract modifications could affect accounting for advance deposits; advance ticket sales for entertainment events; unpaid liabilities for ticket-in, ticket-out coupons (commonly referred to as “TITO coupons”); and race and sports wagers.

- Evaluation of key assumptions for estimating the customer loyalty program obligations since prolonged property closures and lower demand can affect such assumptions (e.g., estimated breakage of loyalty points). Changes to customer loyalty programs in light of current conditions, such as an entity’s decision to voluntarily extend expiration terms, should be monitored and evaluated; these changes may result in more frequent revisions to breakage assumptions and estimates.

- Impairment of long-lived assets, including goodwill and other intangibles; management and franchise agreements; equity method investments; and PP&E.

- Valuation of key monetary assets for those amounts that have been capitalized for cash payments to customers (e.g., hotel owners) in connection with obtaining a franchise, a management agreement, or both. Key monetary payments are generally used by hotel owners to finance new hotel developments or major property renovations and are generally refundable to the franchisor or manager if the franchise or management contract is terminated.
• Liquidity and going-concern considerations resulting from declining revenues, which are driven by lower occupancy and declining price indicators (e.g., average daily rate) that will affect entities in this sector and are likely to be accompanied by additional costs associated with sanitization expenses, spoilage at food and beverage outlets, crisis management fees, expenditures related to cancellations of entertainment and convention events, and payroll and legal costs. Reductions in such metrics can pose significant challenges related to covenant compliance, liquidity, and going-concern issues.

• Close monitoring, in light of potential workforce shortages, of (1) casino entities' regulatory compliance and (2) minimum internal control requirements (as applicable) that are established and mandated by the relevant jurisdictional licensing bodies. Entities will also need to continue monitoring any existing and potential changes to regulatory requirements related to processes and procedures to be performed in the event of a temporary shutdown of gaming establishments.

**Restaurants and Food Services**

As a result of government-imposed closures, limitations on operating hours and services, professional sport league shutdowns, and uncertainties experienced by customers about the overall economy, many are staying at home and thereby reducing demand at restaurant and food service companies.

Noteworthy accounting considerations include:

• Evaluation of the accounting for, and estimation of amounts payable to, a franchisor for advertising funds and royalties in periods in which revenue at the franchisee level is significantly reduced or eliminated (e.g., evaluation of minimum payments in a contract).

• Evaluation of inventory for amounts that may not be salable before spoilage in geographies with significant closures.

• Evaluation of tenant occupancy clauses, which may provide rent relief if the mall, plaza, or center becomes vacant because of the prolonged effects of COVID-19.

• Impairment of long-lived assets (e.g., goodwill and other intangibles; ROU assets; and PP&E).

• Evaluation of key assumptions for estimating the customer loyalty program obligations since prolonged closures and lower demand can affect such assumptions (e.g., estimated breakage of loyalty points). Changes to customer loyalty programs in light of current conditions, such as an entity's decision to voluntarily extend expiration terms, should be monitored and evaluated; these changes may result in more frequent revisions to breakage assumptions and estimates.

• Liquidity and going-concern considerations resulting from potentially prolonged declines in revenue and demand.

**Cruise Lines**

Global cruise operations have experienced adverse effects of the spread of COVID-19, including growing port restrictions around the world. The cruise line sector is affected by many of the same factors that affect not only the airlines, restaurants, and retailers, but also hotels, where significant events affecting travel, including COVID-19, have an adverse impact on booking patterns. The extent of this effect is generally determined by the length of time in which the event influences travel decisions. The decline in global bookings for cruise line travel is exerting significant pressure on cruise lines operations. While reduced oil prices may have a positive impact on the cruise lines once they resume operations, the potential for significant reduction of future global bookings due to consumer sentiment and access to port locations remains a significant uncertainty. Prolonged reductions in consumer demand and related forward bookings will have an adverse impact on the overall liquidity of these companies, and many of them are taking actions to improve liquidity. Such actions include reducing capital expenditures and operating expenses, as well as evaluating other financing alternatives.
Noteworthy accounting considerations include:

- Impairment of long-lived assets (e.g., ships, goodwill and other intangibles) due to reductions in utilization and closed ports, profitability challenges resulting from declines in revenue and demand, and sharp declines in stock prices.

- Liquidity and financing considerations related to servicing debt obligations resulting from potentially prolonged declines in revenue and demand.

- Restructuring considerations related to potential staff reductions due to reductions in cruise itineraries or halting of sailing altogether.

- Evaluation of revenue recognition related to changes in cancellation policies, the associated impacts on performance obligations, and stand-alone selling prices. Entities are experiencing significant cancellations and postponements of cruise line reservations for which advance sales amounts and deposits may have been collected.

- Liquidity and going-concern considerations resulting from declining revenues, which are driven by paused global fleet operations or lower occupancy and potentially declining ticket prices; these declines in revenue are likely to be accompanied by additional operating costs associated with sanitation expenses, crisis management fees, cancellation-related expenditures, and payroll and legal costs. Reductions in such metrics can pose significant challenges related to covenant compliance, liquidity, and going-concern issues.

Retail Sector

The retail sector is facing a number of challenges related to the impact of COVID-19. While some big-box mass merchants and supermarkets are seeing spikes in traffic, other retailers have been experiencing declines in traffic as consumers adjust their shopping patterns. In addition, many retailers have temporarily closed stores, and more retailers may choose to close for the short term as the pandemic evolves. There has been a shift in sales from in-store to online, which may increase shipping costs to the extent that they are not fully passed on to consumers.

Entities in the sector have also experienced disruptions in the supply chain, including those related to (1) competition for suppliers when acquiring raw materials, (2) decreased manufacturing capacity in certain locations, and (3) transportation patterns for merchandise. Many retailers are assessing the impact of production delays on inventory assortments and are considering options to mitigate the impact of such delays, including (1) a reassessment of the normal inventory logistics patterns and (2) increased use of air freight if available.

As a result of concerns about the workforce (corporate and store employees alike), employees may work remotely or be furloughed. Further, certain retailers that had been facing operational challenges before the pandemic, or that have high leverage ratios, could experience liquidity challenges if they are unable to adequately manage inventory, payroll, and rent during any prolonged period of revenue decline.

Noteworthy accounting considerations include:

- Costs related to potential staffing reductions due to store closures or significant declines in traffic.

- The impact of tenant occupancy clauses, which may provide rent relief if the mall or center becomes vacant.

- Negotiated rent relief provided by landlords, if available.

- Impairment of long-lived assets (e.g., store assets, ROU assets, goodwill and other intangibles) due to reductions in revenue and gross margin and possible declines in the stock prices of major retailers. Although depreciation generally does not cease when an asset is temporarily idled, if a retailer determines that operations will be restructured in response to the impact of the pandemic, impairment and useful lives of long-lived assets will need to be considered.

- Inventory obsolescence if a retailer will not be able to sell through merchandise.

- Penalties for any order cancellations, to the extent applicable.

- Changes in the volume or patterns of discounts and allowances provided to customers, which may affect revenue recognition.
• The potential to receive discounts or allowances from vendors if purchasing and sales volumes drop, which may affect the cost of revenue.

• Liquidity and financing considerations related to servicing debt obligations and covenant compliance, including the assessment of going concern, if revenue declines are significant.

• The consistent application of an SEC registrant’s definition of same-store sales and other metrics, or transparent disclosure of any changes to such metrics.

Automotive Sector

The automotive industry has historically been a significant contributor to the global economy and has been widely exposed to many potential risks arising from COVID-19. These risks, include, but are not limited to, the following:

• Potential disruptions to global supply chains and the resulting disruption of production for original equipment manufacturers (OEMs) and suppliers.

• Impacts on consumer confidence and behavior that could potentially reduce consumer demand for automotive products and services. Such impacts could affect the entire automotive sector, including OEMs, suppliers, and retailers (independent automotive dealers and independent automotive parts and service retailers).

• Negative impacts on the global financial and credit markets, which could affect automotive companies’ access to existing or new capital or could increase the cost of capital for automotive companies.

Noteworthy accounting considerations that may arise for the automotive sector include:

• Impairment of nonfinancial assets (e.g., long-lived assets, amortized intangibles) — Significant disruptions to supply or production, declines in consumer demand, or other relevant impacts may (1) represent events or changes in circumstances that indicate that the carrying amounts of certain nonfinancial assets might not be recoverable (requiring impairment tests for the affected nonfinancial assets) or (2) result in the abandonment or permanent idling of long-lived assets (resulting in accelerated depreciation or impairment charges).

• Impairment of goodwill and indefinite-lived intangible assets — Events and circumstances resulting from COVID-19 that indicate that it is more likely than not that the fair values of reporting units with goodwill and indefinite-lived intangible assets are less than the reporting units’ carrying amounts would require interim impairment tests of goodwill and indefinite-lived intangibles between annual impairment testing dates.

• Inventory valuation — Periods of abnormally low production (for OEMs and suppliers) may limit the capitalization of certain costs (e.g., fixed overhead costs) in inventory. In addition, changes in consumer preferences or demand may affect the valuation of inventory held by automotive retailers (as well as OEMs and suppliers) or may result in excessive inventory levels.

• Revenue recognition — Changes in consumer preferences and demand may require OEMs to offer new incentive programs or maintain existing incentive programs for longer than expected. Doing so could have revenue recognition (variable consideration) implications for OEMs or make dealers more dependent on OEMs to move their inventories.

• Restructuring activities — In response to the impacts of COVID-19, automotive companies may implement restructuring actions (e.g., layoffs, contract terminations), the accounting for which can vary depending on the nature of the restructuring activity (e.g., voluntary vs. involuntary terminations, one-time termination benefits vs. benefits provided in accordance with a preexisting plan).

• Credit losses — The financial health of automotive companies’ customers and, therefore, the collectibility of financial assets held by automotive companies, such as accounts receivable (including dealers’ receivables from OEMs under incentive and other programs) and loans receivable (particularly for OEMs with captive financing subsidiaries) may be adversely affected. Any credit losses will need to be evaluated under ASC 310 or ASC 326, as applicable.
Appendix B — Entities Reporting Under IFRS Standards

The accounting and financial reporting considerations discussed in this publication are equally relevant to entities reporting under IFRS Standards. For example, it is likely that an indicator of impairment of PP&E under U.S. GAAP would also be an indicator of impairment under IFRS Standards. However, the underlying accounting guidance itself (e.g., the impairment test) often differs. For a comprehensive discussion of the differences between the two sets of standards, see Deloitte’s *A Roadmap to Comparing IFRS Standards and U.S. GAAP: Bridging the Differences*.

The table below lists the major topics discussed in this publication, the relevant IFRS Standards and U.S. GAAP, and the sections of Deloitte’s *A Roadmap to Comparing IFRS Standards and U.S. GAAP: Bridging the Differences* in which they are discussed in detail.

<table>
<thead>
<tr>
<th>Topic</th>
<th>IFRS Standards</th>
<th>U.S. GAAP</th>
<th>Discussion in A Roadmap to Comparing IFRS Standards and U.S. GAAP: Bridging the Differences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impairment — PP&amp;E and finite-lived intangible assets</td>
<td>IAS 36</td>
<td>ASC 350 and ASC 360</td>
<td>Section 1.7</td>
</tr>
<tr>
<td>Impairment — indefinite-lived intangible assets and goodwill</td>
<td>IAS 36</td>
<td>ASC 350</td>
<td>Section 1.7</td>
</tr>
<tr>
<td>Leases</td>
<td>IFRS 16</td>
<td>ASC 842</td>
<td>Section 5.7</td>
</tr>
<tr>
<td>Inventory</td>
<td>IAS 2</td>
<td>ASC 330</td>
<td>Section 1.4</td>
</tr>
<tr>
<td>Contingencies (including restructurings)</td>
<td>IAS 37</td>
<td>ASC 420 and ASC 450</td>
<td>Section 2.2</td>
</tr>
<tr>
<td>Revenue recognition</td>
<td>IFRS 15</td>
<td>ASC 606</td>
<td>Section 3.1</td>
</tr>
<tr>
<td>Consolidation</td>
<td>IFRS 10 and IFRS 12</td>
<td>ASC 810</td>
<td>Section 5.2</td>
</tr>
<tr>
<td>Foreign currency transactions</td>
<td>IAS 21</td>
<td>ASC 830</td>
<td>Section 5.6</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>IAS 19 and IFRIC Interpretation 14</td>
<td>ASC 420, ASC 710, ASC 712, and ASC 715</td>
<td>Section 2.1</td>
</tr>
<tr>
<td>Share-based payments</td>
<td>IFRS 2</td>
<td>ASC 718</td>
<td>Section 3.2</td>
</tr>
<tr>
<td>Impairment — financial assets</td>
<td>IFRS 9 and IAS 28</td>
<td>ASC 310, ASC 320, ASC 321, ASC 323, and ASC 326</td>
<td>Sections 1.1, 1.2, and 1.3</td>
</tr>
<tr>
<td>Derivatives and hedging</td>
<td>IFRS 9</td>
<td>ASC 815</td>
<td>Section 5.3</td>
</tr>
<tr>
<td>Fair value</td>
<td>IFRS 13</td>
<td>ASC 820</td>
<td>Section 5.4</td>
</tr>
<tr>
<td>Debt modifications and extinguishments</td>
<td>IFRS 9</td>
<td>ASC 470-50 and ASC 470-60</td>
<td>Section 2.3</td>
</tr>
<tr>
<td>Depreciation</td>
<td>IAS 16</td>
<td>ASC 360</td>
<td>Section 1.6</td>
</tr>
<tr>
<td>Noncurrent assets held for sale and discontinued operations</td>
<td>IFRS 5</td>
<td>ASC 360-10 and ASC 205-20</td>
<td>Section 4.2</td>
</tr>
<tr>
<td>Government grants</td>
<td>IAS 20</td>
<td>None*1</td>
<td>Section 5.9</td>
</tr>
<tr>
<td>Income taxes</td>
<td>IAS 12 and IFRIC Interpretation 23</td>
<td>ASC 740</td>
<td>Section 3.3</td>
</tr>
<tr>
<td>Presentation of financial statements</td>
<td>IAS 1</td>
<td>ASC 205-10, ASC 220-10, ASC 505-10, ASC 810-10, and SEC Regulation S-X</td>
<td>Section 4.1</td>
</tr>
<tr>
<td>Statement of cash flows</td>
<td>IAS 1 and IAS 7</td>
<td>ASC 230-10</td>
<td>Section 4.3</td>
</tr>
<tr>
<td>Subsequent events</td>
<td>IAS 10</td>
<td>ASC 855</td>
<td>Section 5.9</td>
</tr>
</tbody>
</table>

*1 Under U.S. GAAP, there is no explicit guidance related to government grants or other forms of government assistance, other than industry guidance for not-for-profit entities.
Appendix C — Deloitte Contacts and Acknowledgments

Contacts
If you have questions about the information in this publication, please contact any of the following Deloitte professionals:

Christine Davine
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 202 879 4905
cdavine@deloitte.com

Curt Weller
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 415 783 4995
cweller@deloitte.com

Brandon Coleman
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 312 486 0259
brcoleman@deloitte.com

Andy Elcik
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 212 492 3811
aelcik@deloitte.com

Chris Rogers
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 202 220 2695
chrrogers@deloitte.com

Steve Barta
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 415 783 6392
sbarta@deloitte.com

Chris Chiriatti
Managing Director
Audit & Assurance
Deloitte & Touche LLP
+1 203 761 3039
ccchiriatti@deloitte.com

Ruth Uejio
Partner
Audit & Assurance
Deloitte & Touche LLP
+1 415 783 4876
ruejio@deloitte.com
Acknowledgments

Curt Weller supervised the overall preparation of this publication and extends his deepest appreciation to the professionals in Deloitte’s Professional Practice Network who helped develop the publication. He is particularly grateful for the leadership and technical contributions of Ruth Uejio, John Wilde, and Greg Bartholomew.

Curt would also like to thank the following:

- Deloitte Accounting and Reporting Services team leaders and subject matter experts for their technical contributions to the publication, including James Barker, Ashley Carpenter, Brandon Coleman, Mark Crowley, Matt Himmelman, Jonathan Howard, Dennis Howell, Sandie Kim Kulick, Patrice Mano, Sean May, Mark Miskinis, Lisa Mitrovich, Michael Morrissey, Ignacio Perez, Doug Rand, Stefanie Tamulis, Bob Uhl, and Andy Winters.


- Senior leaders of Deloitte’s Professional Practice Network, including Doug Barton, Dora Burzinski, Christine Davine, Jennifer Haskell, and Dan Sunderland.

Finally, Curt wishes to express his immense gratitude for the editorial and production efforts of Teri Asarito, Lynne Campbell, Sandy Cluzet, Geri Driscoll, David Eisenberg, Dave Frangione, Adrienne Julier, Michael Lorenzo, Jeanine Pagliaro, and Lazaros Perisanidis.
Appendix D — Summary of Changes

Substantive updates were made to the following sections on April 13, 2020, to reflect changes as a result of the CARES Act and other accounting and financial reporting developments:

Executive Summary

Select SEC and PCAOB Announcements Related to COVID-19

Financial Instruments and Contract Assets — Impairment and Valuation Considerations

Financial Instruments and Contract Assets — Transfers/Sales of HTM Investments

Financial Instruments and Contract Assets — Transfers of Investments Into or Out of Trading Classification [Added]

Financial Instruments and Contract Assets — Impact on Hedge Accounting

Financial Instruments and Contract Assets — Fair Value Measurement and Disclosures

Revenue Contracts With Customers

Lease/Rent Concessions

Government Assistance

Banking and Finance Industry — Financial Instruments — Impairment and Valuation Considerations

Banking and Finance Industry — Troubled Debt Restructurings

Banking and Finance Industry — Interest Income During Payment Holidays [Added]

Real Estate Industry — Rent Relief and Other Support for Tenants

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

The services described herein are illustrative in nature and are intended to demonstrate our experience and capabilities in these areas; however, due to independence restrictions that may apply to audit clients (including affiliates) of Deloitte & Touche LLP, we may be unable to provide certain services based on individual facts and circumstances.

As used in this document, “Deloitte” means Deloitte & Touche LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of our legal structure.

Copyright © 2020 Deloitte Development LLC. All rights reserved.